ANNUAL STATEMENT

OF THE

Athene Annuity and Life Company

TO THE

Insurance Department

OF THE

STATE OF

FOR THE YEAR ENDED DECEMBER 31, 2018

LIFE AND ACCIDENT AND HEALTH

2018

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)	37,954,373,669		37,954,373,669	38,988,956,533
	Stocks (Schedule D):				
	2.1 Preferred stocks	121,789,115		121,789,115	99,055,975
	2.2 Common stocks	477,529,433		477,529,433	
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	6,070,077,813		6,070,077,813	3,759,406,453
	3.2 Other than first liens	1,639,441,726		1,639,441,726	1,056,900,553
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)				
	4.2 Properties held for the production of income (less				
	\$ encumbrances)	9,388,542		9,388,542	9,388,542
	4.3 Properties held for sale (less \$				
	encumbrances)	57,000		57,000	10,120,190
5.	Cash (\$(3,207,920), Schedule E - Part 1), cash equivalents				
	(\$, Schedule E - Part 2) and short-term				
	investments (\$1,447,460,817 , Schedule DA)	1,444,252,897		1,444,252,897	3, 176, 100, 220
6.	Contract loans (including \$ premium notes)	189,508,910		189,508,910	210,007,248
7.	Derivatives (Schedule DB)	749,445,723		749,445,723	538,873,546
8.	Other invested assets (Schedule BA)	1,989,363,042	94,300	1,989,268,742	1,759,688,365
9.	Receivables for securities	46,185,084		46,185,084	29,028,154
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets	42,236,577		42,236,577	81,823,229
	Subtotals, cash and invested assets (Lines 1 to 11)			50,733,555,231	
13.	Title plants less \$ charged off (for Title insurers				
	only)				
14.	Investment income due and accrued	437,839,861	338,563	437,501,299	435,422,321
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	4,123		4, 123	2,049
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)	8,112,340		8,112,340	8,862,199
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$				
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	211,730,978		211,730,978	159,277,853
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts	1, 148, 353, 301		1, 148, 353, 301	1,489,144,846
17.	Amounts receivable relating to uninsured plans				
18.1	Current federal and foreign income tax recoverable and interest thereon				18,611,932
18.2	Net deferred tax asset	19,381,825		19,381,825	
19.	Guaranty funds receivable or on deposit	11,689		11,689	42,528
20.	Electronic data processing equipment and software				
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$) and other amounts receivable	50,110,541	3,942,756	46,167,786	1,240,453
25.	Aggregate write-ins for other than invested assets	364,914,876	2,384,179	362,530,697	349,975,052
26.	Total assets excluding Separate Accounts, Segregated Accounts and	EO 074 E07 E0.	0.750.70	FO 007 777 707	EO EO4 000 445
	Protected Cell Accounts (Lines 12 to 25)	52,974,537,584	Lb,/59,/9/	52,967,777,787	52,584,266,116
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	5.029.174.416		5,029,174,416	2.349.017.849
28.	Total (Lines 26 and 27)	58,003,712,000	6,759,797	57,996,952,203	54,933,283,965
	DETAILS OF WRITE-INS		, ,	, , ,	, , ,
1101.	Derivative Collateral Asset	42.236.577		42,236,577	81,823,229
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page				
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	42,236,577		42,236,577	81,823,229
	Corporate Owned Life Insurance (COLI)			361,748,235	349,471,527
	Miscellaneous Assets			782,462	503.525
	Prepaid Expenses		, , ,	· · · · · · · · · · · · · · · · · · ·	
	Summary of remaining write-ins for Line 25 from overflow page				
	, ,	364,914,876	2,384,179	362,530,697	349,975,052
<u> </u>	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	004,010	2,004,1/9	JUZ, JJU, US/	JU1, 015, 5FU

LIABILITIES, SURPLUS AND OTHER FUNDS

26. Total liabilities excluding Separate Accounts business (Lines 1 to 25) 52,053,109,683 51,568,599,864 27. From Separate Accounts Statement 4,709,678,697 2,200,475,445 28. Total liabilities (Lines 26 and 27) 56,762,788,380 53,769,075,309 29. Common capital stock 10,000,000 10,000,000 30. Preferred capital stock 10,000,000 10,000,000 31. Aggregate write-ins for other than special surplus funds 20 20 32. Surplus notes 32	1	•	1	2
Application control of the State Indication of State			Current Year	
2. A prographic reserve for acciditation for including \$ 1, 1482, 309. Moders Reservery (15, 20), 522, 705. 2. Licellilip for deposition place contames (Entity) T. Line 14, Care 17, 10 (14), 1	1.	Aggregate reserve for life contracts \$44,937,658,234 (Exh. 5, Line 9999999) less \$		
1. Lichtley for departed oper commons (Enhalt 7. Lims 14. Cel. 1) (including \$ 384,473,700 Modes Reserve)		included in Line 6.3 (including \$35,963,522,487 Modco Reserve)	44,937,658,234	43,240,460,487
4. Contract claims: 4. 1.1.1.6. (EURIDE 6) First 1, Lime 4 x, Cod. 1 layes can of colo. 8. 1 Stand 11) 5. Proliphydoser dividence and coupons 8 years of the analysis of the analysis of the proliphydoser dividence and coupons 8 years of the color of the		Aggregate reserve for accident and health contracts (including \$1,842,589 Modco Reserve)	3,589,927	5,382,796
4.1 Life (Exhibit & Part 1. Life 4.4 Cot. 1 fees sown OCat. 9, 10 and 11). 4.2 A Accident and rewish (Exhibit 8). 4. A recident and rewish (Exhibit 8). 5. Prolykological circles of the 1. Life 4.4, same (Dob. 8, 10 and 11). 5. Prolykological circles of the 1. Life 4.4, same (Dob. 8, 10 and 11). 6. Dividends approximent of treatment (including 8). 6. Dividends approximent of treatment (including 8). 6. Modes: 6. Dividends approximent of the angenote people in following circles and treatment of the 1. Life			435,597,932	521,821,966
4.2 Accident and health Excitation Chains () Part 1. Line 4.4, amm of Cois. 9, 1 and 11) 4. Provision for prolifor federic divisions and coupons payable in following calcularly sear - estimated ammunits 6. Provision for prolifor divisions and coupons payable in following calcularly 30 6. Divisions and payable professions of the common o	4.		000 000 000	004 000 505
5. Performance discharded: a marticulation of companies people in historing calendary pers - estimated amounts; 5. Dividished appointment of celeptines (noticeling a Modos) 6. Dividished appointment for celeptines (noticeling a Modos) 7. S. Coupons and similar becente incustring a Modos) 7. S. Coupons and similar becentes incustring a Modos) 8. S. Coupons and similar becentes incustring a Modos) 8. S. Coupons and similar becentes incustring a Modos) 9. S. Coupons and similar becentes incustring a Modos) 9. S. Coupons and similar becentes incustring a Modos 9. S. S. Coupons and similar becentes incustring a Modos 9. S. S. Coupons and similar because to 10 and accessed and bediend permitters (Cultural 1, 1997) 9. Permitters and analyse consideration of the land accessed and bediend permitters (Cultural 1, 1997) 9. Permitters and analyse consideration of the similar of similar and analyse and analyse and accessed and similar and beattle operations are simple control of which 3 is for medical loss ratio reduce per the Public Health and expenses and common permitters (Cultural 1, 1997) 9. S. Coupons and permitters (Cultural 2, 1997) 9. S. Coupons and permitters (Cultural 3, 1997) 9. S. Coupons and permitters (Cultur		4.1 Life (Extribut o, Patt 1, Life 4.4, Cot. 1 less Suff of Cots. 9, 10 and 11)	200,920,090	
Live 10 Provision for peripherical information and incorpancy regulation in following collection year: estimated amounts: 8 2 Dividence and vive deportioned (including 8 Modos) 8.2 Dividence and vive deportioned (including 8 Modos) 9.3 A Causey and divident of deferred divident platities and included in the Exercise Control of the Section of the Se	5	4.2 Accident and realin (Exhibit 6, Fatt 1, Line 4.4, Sull of Color, 9, 10 and 11)	12,000	14, 132
6. Provision for policyholdenic dividends and courson psystella in following calendary sear- estimated amounts: 6. 1 Dividendors proprieted for page-particular for page-page-page-page-page-page-page-page-	5.	Line 10) and coupons \$ and coupons \$ ude and unpaid (Exhibit 4,		
6.1 Dividence apportioned for pagment (including \$ Motion) 6.2 Dividence in one importance (including \$ Motion) 7.3 Cauptons and similar including \$ Motion 7.4 Permitters and among an acceptance of file and accident and earlier context in advanced seas. 8. Surround values on canacted contracts 8. Surround values on canacted values values on canacted values on canacted values on canacted values values on canacted values values on canacted values values on canacted values values values on canacted values values values on canacted values v	6	Provision for policyholdars' dividende and coupons payable in following calendar year - estimated amounts:		
6.2 Diocenda nat yet approximate (including 5 6.3 Coupton and initial hardware limited and including 5 6.4 Coupton and initial hardware limited in the second in the secon	0.	F10/ision to policyticides university and coupons payable in following calendar year - estimated amounts.		
. Compose and seminar benefits (including \$		6.2 Dividends not yet apportioned (including \$ Modo)		
7. Amount provisionally held for deferred dividend policies not included in time 6. Persimular and annuly conselectors for lies and according an inhalting control seasoned in advance less. Persimular and annuly conselectors for lies and according and season. Pers 1, Col. 1, sum of time 4 and k1. 2. Contract billiaise and included deservatives. 3. Summeder values or controlled controls. Service Act. 3. Summeder values or controlled controls. Service Act. 3. Summeder values or controlled controls. Service Act. 3. Controlled billiaise and included deservatives. Including to its for medical loss ratio relates per the Patiet Health Service Act. 3. Controlled billiaise and included deservatives. Including 5. accessed. 3. Service Act. 3. Controlled billiaise and included deservatives. Including 5. accessed. 4. Service Act. 3. Life, 144, 235 2.		0.2 Dividents not yet appointment (including \$ Modes)		
6. Premums and annuly considerations for the and academ and health contracts excelved in advanced less 8 part 1, 50.5, 1, annul of all of and 14 part 14 part 1, annul of annul 14 part 1, annul 14 part 14 pa	7			
## discount: including \$ 4.505 accident and health premiume (E-hibit 1, Part 1, Col. 1, sum of lines 4 and 14 4) Comment shallfilling and included alterowhers:				
Part 1, Col. 1, sum of lines 4 and 14)	0.			
9. Contract fabilities not included elevatives. 9.1 Surreided values on careage returns. 9.2 Provision for agreement returns or starg returns. 9.3 Provision for agreement returns a contract such as accident and health Service Act. 9.2 Other emounts payable on reinsurance, including \$ 4. Service and the service of the contract such as accident and health Service Act. 9.2 Other emounts payable on reinsurance, including \$ 4. Service on the gents due or accounted life and annually centracts \$ 9. Service on the gents due or accounted life and annually centracts \$ 9. Service on the gents due or accounted life and annually centracts \$ 9. Service on the gents due or account of the provision of the service			4 505	4 628
9 Summer's values on canceled contracts 2-9. Provision for experience string refunds, including the liability of \$ 2-9. Provision for experience string refunds of which \$ 2-9. Softwar another psycholor or returnations, including \$ 3. Software string refunds of which \$ 3. Software string refunds on the string refunds of the strin	9		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
9.2 Provision for experience rating refunds, including the liability of 8 source or large funds or which \$ is for medical loss ratio rebates or the Public Health Service Act. 9.1 Annual Service Act. 9.2 An interest maintenance reserve (MRF, Line 6) 1. 986, 144, 225 1. 986, 144, 225 1. 986, 144, 225 1. 1986, 14	0.			
seperience rating refunds of which \$ is for medical loss ratio relate per the Public Health Service Nat! 9.3 Other amounts payable on reinsurance, including \$ issuand and \$ 1,550,144,255 9.4 Interest maintenance reserved (MR Line 6) 10. Commissions to agents claim or advantage of the commissions of the commissions and experience allowances payable on reinsurance assumed 11. Commissions and experience allowances payable on reinsurance assumed 12. Commissions and experience allowances payable on reinsurance assumed 13. Commissions and experience allowances payable on reinsurance assumed 14. SST, 456 15. Commissions and experience allowances payable on reinsurance assumed 16. Commissions and experience allowances payable on reinsurance assumed 17. Commissions and experience and experience and experience and resolution of control, and analysis of the payable on reinsurance assumed 18. Tarest, licenses and reles due or accordance, declaring decental income traces (Exhibit 2. Line 9, Cot. 5) 18. SST, 255 19. Taresters in Signature Machanism of the control of				
Service Act 9.3 Other amounts payable on reineurance, including \$ assumed and \$ 1,556,144,255 1,356,144,255 2,157,442,255		experience rating refunds of which \$ is for medical loss ratio rebate per the Public Health		
9.3 Other amounts payable on retreasurance, including \$		Service Act		
Code				
9. 4 Interest maintenance reserve (IMR. Line 6)			1 956 144 235	2 137 442 635
10. Commissions to agents due or accrued-life and annuity contracts \$ 11,155,010 \$.8,87,200 \$.8,87,200 \$.8,87,200 \$.2,211 \$.8,87,200 \$.2,211 \$.8,87,200 \$.7,23,131 \$.8,87,200 \$.7,23,131 \$.8,87,200 \$.7,23,131 \$.7,				
\$ and deposit type contract funds \$ 11, 155, 010 2, 887, 202 2, 241 12, Commissions and exposes guide non-instruction assumed 2, 241 26, General exposuration or accrued (Erbital 2, Line 12, Col. 6) 11, 597, 495 12, 233, 187 12, 233, 187 12, 233, 187 13, 233, 187 14, 187, 495 14, 18	10.			
1.1 Commissions and expenses allowances payable on reinsurance assumed			11 155 010	8 887 290
12 General expenses due or accrued (Exhibit 2, Line 12, Col. 6) 1, 547,465 12, 233,787 13, Transfers to Separata Accounts due or accrued (review) (including \$ (133) accrued for expense all downces recognized in reserves, net of reinsured allowances) 1,090,112,530 571,3787 13, 200 13, 200 13, 200 13, 200 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 14, 239,937 15, 239,939 14, 239,937 15, 239,939 14, 239,937 15, 239,939 14, 239,937 15, 239,939 15, 239,9	11.			
1. Transfers to Separate Accounts due or accrued (net) (including \$		General expenses due or accrued (Exhibit 2, Line 12, Col. 6)	14.547.495	12.233.187
allowances recognized in reserves, net of reinsured allowances)		Transfers to Separate Accounts due or accrued (net) (including \$ (133) accrued for expense		
14. Taxes, licenses and refers due or accorder, excluding federal income taxes (Exhibits, 3, Line 8, Col. 5)		allowances recognized in reserves, net of reinsured allowances)	1.050.112 530	671.373 538
15.5 Current federal and foreign income taxes, including \$ 24,77,096 on realized capital gains (losses)	14.	Taxes, licenses and fees due or accrued, excluding federal income taxes (Exhibit 3, Line 9, Col. 5)	13 800	9 464 094
15.2 Net deferred tax liability		Current federal and foreign income taxes, including \$ 24 777 096 on realized capital gains (losses)	41 259 937	
16. Unsamed investment income	15.2	Net deferred tax liability		
17. Amounts withheld or retained by company as agent or trustee 2, 231, 466 5, 500, 221 18. Amounts held for agents' account, including \$ \$ 3, 397, 955 agents' credit balances 3, 367, 955 19. Remittances and items not allocated 177, 677, 747, 255 19. Remittances and items not allocated 177, 677, 747, 255 19. Remittances and items not allocated 177, 747, 255 19. Remittances and items not allocated 177, 747, 255 19. Remittances and items not allocated 177, 747, 255 21. Liability for benefits for employees and agents if not included above 42, 809, 662 43, 647, 206 22. Borrowed money \$ 24, 289, 662 43, 647, 206 23. Dividends to stockholders declared and unpaid 24, 24, 24, 24, 24, 24, 24, 24, 24, 24,			3 020 170	327 550
18. Amounts held for agents' account, including \$ 3,587,955 agents' credit balances 3,87,955 1,581,057 77,74,255		Amounts withheld or retained by company as agent or trustee	2 231 406	
	18.			
20. Net adjustment in assets and liabilities due to foreign exchange rates 42,809,662 43,647,268		Remittances and items not allocated	157.657.501	75.724.525
1. Liability for benefits for employees and agents if not included above				
Borrowed money \$ and interest thereon \$		Liability for benefits for employees and agents if not included above	42.809.662	43.647.206
Dividends to stockholders declared and unpaid	22.	Borrowed money \$ and interest thereon \$		
Miscellaneous liabilities: 24.01 Rasset valuation reserve (AVR, Line 16, Col. 7) 544, 533, 824 560, 834, 859 24.02 Reinsurance in unauthorized and certified (\$) companies 1, 141, 232, 746 1, 449, 285, 554 24.04 Payable to parent, subsidiaries and affiliates 14, 025, 316 20, 013, 267 24.05 Tailor soutsanding 24.05 Liability for amounts held under uninsured plans 24.07 Funds held under roinisurance 24.08 Derivatives 39, 463, 437 67, 810, 242 24.09 Payable for securities 24.08 Derivatives 24.08 Derivatives 24.09 Payable for securities 24.10 Pa	23.	Dividends to stockholders declared and unpaid		
24.02 Reinsurance in unauthorized and certified (\$) companies. 24.03 Funds held under reinsurance treaties with unauthorized and certified (\$) reinsurers 14.02 5,316 24.04 Payable to parent, subsidiaries and affiliates 24.05 Lability for amounts held under uninsured plans 24.05 Lability for amounts held under uninsured plans 24.06 Lability for amounts held under uninsured plans 24.07 Funds held under coinsurance 24.08 Derivalives 24.09 Payable for securities 24.09 Payable for securities lending 24.10 Payable for securities lending 24.10 Payable for securities lending 24.10 Payable for securities lending 24.11 Payable for securities lending 24.10 Payable for securities lending 24.11 Payable for securities lending 25. Total liabilities excluding Separate Accounts business (Lines 1 to 25) 26. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 877 4, 709, 676, 897 4, 709, 676, 897 4, 700, 700, 700 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 4, 709, 676, 897 4, 700, 700, 700 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 7. Surplus of total Lines 31, 64, 64, 64, 64, 64, 64, 64, 64, 64, 64	24.			
24.02 Reinsurance in unauthorized and certified (\$) companies. 24.03 Funds held under reinsurance treaties with unauthorized and certified (\$) reinsurers 14.02 5,316 24.04 Payable to parent, subsidiaries and affiliates 24.05 Lability for amounts held under uninsured plans 24.05 Lability for amounts held under uninsured plans 24.06 Lability for amounts held under uninsured plans 24.07 Funds held under coinsurance 24.08 Derivalives 24.09 Payable for securities 24.09 Payable for securities lending 24.10 Payable for securities lending 24.10 Payable for securities lending 24.10 Payable for securities lending 24.11 Payable for securities lending 24.10 Payable for securities lending 24.11 Payable for securities lending 25. Total liabilities excluding Separate Accounts business (Lines 1 to 25) 26. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 877 4, 709, 676, 897 4, 709, 676, 897 4, 700, 700, 700 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 4, 709, 676, 897 4, 700, 700, 700 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 7. Total liabilities excluding Separate Accounts Statement 4, 709, 676, 897 7. Surplus of total Lines 31, 64, 64, 64, 64, 64, 64, 64, 64, 64, 64		24.01 Asset valuation reserve (AVR, Line 16, Col. 7)	644,533,824	560,834,859
24.03 Funds held under reinsurance treaties with unauthorized and certified (\$) reinsurers				
24.04 Payable to parent, subsidiaries and affiliates				
24.05 Drafts outstanding				
24.06 Liability for amounts held under uninsured plans 24.07 Prunds held under coinsurance 24.08 Derivatives 24.08 Derivatives 24.09 Payable for securities 24.10 Payable for securities tending 24.11 Capital notes \$ 24.11 Capital notes \$ 24.11 Capital notes \$ 25. Aggregate write-ins for liabilities 29.0,200,423 22.282,774,076 26. Total liabilities excluding Separate Accounts business (Lines 1 to 25) 27. From Separate Accounts Statement 28. Aggregate write-ins for liabilities 29. Common capital stock 20. Exparate Accounts Statement 29. Exparate Accounts Statement 20. Ex		24.05 Drafts outstanding		
24.08 Derivatives				
24.08 Derivatives		24.07 Funds held under coinsurance		
24.10 Payable for securities lending				
24.11 Capital notes \$ and interest thereon \$ 24.11 Capital notes \$ 940, 230, 423 2, 282, 774, 076 26. Total liabilities (increase Accounts business (Lines 1 to 25)		24.09 Payable for securities	21,332,390	83, 136, 860
24.11 Capital notes \$ and interest thereon \$ 24.11 Capital notes \$ 940, 230, 423 2, 282, 774, 076 26. Total liabilities (increase Accounts business (Lines 1 to 25)		24.10 Payable for securities lending		
25. Aggregate write-ins for liabilities excluding Separate Accounts business (Lines 1 to 25)				
27. From Separate Accounts Statement 4,709,678,697 2,200,475,445 28. Total liabilities (Lines 26 and 27) 55,762,788,380 53,769,075,309 29. Common capital stock 10,000,000 10,000,000 30. Preferred capital stock 10,000,000 10,000,000 31. Aggregate write-ins for other than special surplus funds 20,000 952,052,243 927,979,325 32. Surplus notes 33. Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1) 952,052,243 927,979,325 34. Aggregate write-ins for special surplus funds 272,111,580 226,229,331 35. Unassigned funds (surplus) 272,111,580 226,229,331 36.1 shares common (value included in Line 29 \$ 36.2 shares preferred (value included in Line 29 \$) 36.2 shares preferred (value included in Line 30 \$) 1,224,163,823 1,154,206,655 38. Totals of Lines 29, 30 and 37 (Page 4, Line 55) 319,495,719 in Separate Accounts Statement) 1,224,163,823 1,164,206,655 39. Totals of Lines 29 and 38 (Page 2, Line 28, Col. 3) 57,996,952,203 54,933,283,965 DETAILS OF WritE-INS 2501. Derivative Collateral Liability 875,897,195 2,227,195,423 2502. Unclaimed Funds 32,840,690 18,802,	25.	Aggregate write-ins for liabilities	940,230,423	2,282,774,076
27. From Separate Accounts Statement. 4,709,678,697 2,200,475,445 28. Total liabilities (Lines 26 and 27). 56,762,788,380 53,769,075,309 29. Common capital stock. 10,000,000 10,000,000 30. Preferred capital stock. 10,000,000 10,000,000 31. Aggregate write-ins for other than special surplus funds. 55,762,783,300 32,203,424 927,979,325 33. Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1). 952,052,243 927,979,325 34. Aggregate write-ins for special surplus funds. 272,111,580 226,229,331 35. Unassigned funds (surplus). 272,111,580 226,229,331 36. Lass treasury stock, at cost: 36.1 shares preferred (value included in Line 29 \$ 3) 36.2 shares preferred (value included in Line 30 \$) 272,111,580 226,229,331 37. Surplus (Total Lines 31+32+33+44-35-36) (including \$ \$ 319,495,719 in Separate Accounts Statement) 1,224,163,823 1,154,206,655 38. Totals of Lines 29, 30 and 37 (Page 4, Line 55). 57,996,952,003 54,933,283,965 DETAILS OF WRITE-INS 2501. Derivative Collateral Liability 875,837,195 2,227,195,423 2502. Unclaimed Funds 32,940,690 18,802,6	26.	Total liabilities excluding Separate Accounts business (Lines 1 to 25)	52,053,109,683	51,568,599,864
Total liabilities (Lines 26 and 27)	27.	From Separate Accounts Statement		
29. Common capital stock	28.		56,762,788,380	53,769,075,309
30. Preferred capital stock		Common capital stock		
31. Aggregate write-ins for other than special surplus funds 32. Surplus notes 33. Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1) 33. Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1) 34. Aggregate write-ins for special surplus funds 35. Unassigned funds (surplus) 36. Less treasury stock, at cost: 36.1				
Surplus notes Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1) 952,052,243 927,979,325		Aggregate write-ins for other than special surplus funds		
33. Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1)	32.	Surplus notes		
34. Aggregate write-ins for special surplus funds 35. Unassigned funds (surplus) 36. Less treasury stock, at cost: 36.1	33.	Gross paid in and contributed surplus (Page 3, Line 33, Col. 2 plus Page 4, Line 51.1, Col. 1)	952,052,243	927,979,325
35. Unassigned funds (surplus)	34.	Aggregate write-ins for special surplus funds	. , , ,	
36. Less treasury stock, at cost: 36.1 shares common (value included in Line 29 \$) 36.2 shares preferred (value included in Line 30 \$) 37. Surplus (Total Lines 31+32+33+34+35-36) (including \$ 319,495,719 in Separate Accounts Statement) 1,224,163,823 1,154,208,655 38. Totals of Lines 29, 30 and 37 (Page 4, Line 55) 1,234,163,823 1,164,208,655 39. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3) 57,996,952,203 54,933,283,965 DETAILS OF WRITE-INS 2501. Derivative Collateral Liability 875,837,195 2,227,195,423 2502. Unclaimed Funds 32,840,690 18,802,686 2503. Amount Due Reinsurer 30,396,002 10,975,144 2598. Summary of remaining write-ins for Line 25 from overflow page 1,156,536 25,800,823 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) 940,230,423 2,282,774,076 3101. 3102. 3103 3198. Summary of remaining write-ins for Line 31 from overflow page 3199. Totals (Lines 3101 thru 3103 plus 3198)(Line 31 above) 3401. 3402. 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3403. 3408.	35.			
36.2 shares preferred (value included in Line 30 \$)		Less treasury stock, at cost:	, , , ,	, -,
36.2 shares preferred (value included in Line 30 \$)				
37. Surplus (Total Lines 31+32+33+34+35-36) (including \$ 319,495,719 in Separate Accounts Statement)		36.2shares preferred (value included in Line 30 \$)		
38. Totals of Lines 29, 30 and 37 (Page 4, Line 55) 1,234,163,823 1,164,208,655 39. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3) 57,996,952,203 54,933,283,965 DETAILS OF WRITE-INS 2501. Derivative Collateral Liability 875,837,195 2,227,195,423 2502. Unclaimed Funds 32,840,690 18,802,686 2503. Amount Due Reinsurer 30,396,002 10,975,144 2598. Summary of remaining write-ins for Line 25 from overflow page 1,156,536 25,800,823 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) 940,230,423 2,282,774,076 3101. 3102. 3103. 3198. Summary of remaining write-ins for Line 31 from overflow page 3103. 3103. 3103. 3103. 3103. 3103. 3103. 3104. 3104. 3105. 3106. 3107. 3108. 3109.	37.			1,154,208,655
39. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3) DETAILS OF WRITE-INS 2501. Derivative Collateral Liability 2502. Unclaimed Funds 2503. Amount Due Reinsurer 2598. Summary of remaining write-ins for Line 25 from overflow page 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) 3101. 3102. 3103. 3198. Summary of remaining write-ins for Line 31 from overflow page 3199. Totals (Lines 3101 thru 3103 plus 3198)(Line 31 above) 3401. 3402. 3403. 3408. Summary of remaining write-ins for Line 34 from overflow page 3403. 3408. Summary of remaining write-ins for Line 34 from overflow page 357,996,952,203 54,933,283,965 57,996,952,203 54,936,952,203 54,936,952,203 54,933,283,965 5	38.			1,164,208,655
DETAILS OF WRITE-INS 2501. Derivative Collateral Liability 875,837,195 2,227,195,423 2502. Unclaimed Funds 32,840,690 18,802,686 2503. Amount Due Reinsurer 30,396,002 10,975,144 2598. Summary of remaining write-ins for Line 25 from overflow page 1,156,536 25,800,823 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) 940,230,423 2,282,774,076 3101. 3102. 3103. 3103. 3103. 3103. 3103. 3103. 3104. 3105. 3105. 3106. 3106. 3107. 3108. Summary of remaining write-ins for Line 31 from overflow page 3199. Totals (Lines 3101 thru 3103 plus 3198)(Line 31 above) 3401. 3402. 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408. Summary of remaining write-ins for Line 34 from overflow page 3408.	39.	Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3)	57,996,952,203	54,933,283,965
2502 Unclaimed Funds 32,840,690 18,802,686 2503 Amount Due Reinsurer 30,396,002 10,975,144 2598 Summary of remaining write-ins for Line 25 from overflow page 1,156,536 25,800,823 25,990 25,99		DETAILS OF WRITE-INS		*
2502 Unclaimed Funds 32,840,690 18,802,686 2503 Amount Due Reinsurer 30,396,002 10,975,144 2598 Summary of remaining write-ins for Line 25 from overflow page 1,156,536 25,800,823 25,990 25,99	2501.	Derivative Collateral Liability	875,837,195	2,227,195,423
2503. Amount Due Reinsurer 30,396,002 10,975,144 2598. Summary of remaining write-ins for Line 25 from overflow page 1,156,536 25,800,823 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) 940,230,423 2,282,774,076 3101. 3102. 3103. 3108. Summary of remaining write-ins for Line 31 from overflow page 3198. Summary of remaining write-ins for Line 31 from overflow page 3401. 3402. 3403. 3403. 3408. Summary of remaining write-ins for Line 34 from overflow page 3401. 3408. Summary of remaining write-ins for Line 34 from overflow page 3401. 3402. 3403.				
2598. Summary of remaining write-ins for Line 25 from overflow page	2503.	Amount Due Reinsurer	30,396,002	10,975,144
2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) 940,230,423 2,282,774,076 3101. 3102. 3103. 3103. 3103. 3103. 3103. 3103. 3103. 3104. 3105. 3105. 3106. 3106. 3106. 3106. 3107. 3108. Summary of remaining write-ins for Line 31 from overflow page 3109. 3	2598.			
3101. 3102. 3103. 3198. Summary of remaining write-ins for Line 31 from overflow page	2599.			2,282,774,076
3102. 3103. 3198. Summary of remaining write-ins for Line 31 from overflow page. 9 3199. Totals (Lines 3101 thru 3103 plus 3198)(Line 31 above) 9 3401. 9 3402. 9 3403. 9 3498. Summary of remaining write-ins for Line 34 from overflow page 9	3101.			
3103. 3198. Summary of remaining write-ins for Line 31 from overflow page 919. Totals (Lines 3101 thru 3103 plus 3198)(Line 31 above) 919. </td <td></td> <td></td> <td></td> <td></td>				
3198. Summary of remaining write-ins for Line 31 from overflow page				
3199. Totals (Lines 3101 thru 3103 plus 3198)(Line 31 above)				
3401. 3402. 3403. 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page				
3402. 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page				
3403. Summary of remaining write-ins for Line 34 from overflow page				
3498. Summary of remaining write-ins for Line 34 from overflow page				

SUMMARY OF OPERATIONS

	SOMMATT OF OFETATIONS	1	2
1.	Premiums and annuity considerations for life and accident and health contracts (Exhibit 1, Part 1, Line 20.4, Col. 1, less	Current Year	Prior Year
	Col. 11)	1,272,542,499	1,533,886,635
2.	Considerations for supplementary contracts with life contingencies	2,084,517	3,409,074
3.	Net investment income (Exhibit of Net Investment Income, Line 17)	3,331,541,787	2,952,220,487
4. 5.	Amortization of Interest Maintenance Reserve (IMR, Line 5)	(1 793 871)	
6.	Commissions and expense allowances on reinsurance ceded (Exhibit 1, Part 2, Line 26.1, Col. 1)	843,875,751	775,073,607
7.	Reserve adjustments on reinsurance ceded	(1,239,157,364)	655,284,862
8.	Miscellaneous Income:		
	8.1 Income from fees associated with investment management, administration and contract guarantees from Separate Accounts	0 250 024	2 402 724
	8.2 Charges and fees for deposit-type contracts		
	8.3 Aggregate write-ins for miscellaneous income		23,426,162
9.	Total (Lines 1 to 8.3)	4,245,948,272	5,966,218,836
10.	Death benefits	1,912,216	(141,204)
11.	Matured endowments (excluding guaranteed annual pure endowments)		
12.	Annuity benefits (Exhibit 8, Part 2, Line 6.4, Cols. 4 + 8)	237,185,461	177,702,613
13.	Disability benefits and benefits under accident and health contracts Coupons, guaranteed annual pure endowments and similar benefits		
14. 15.	Surrender benefits and withdrawals for life contracts	645 170 390	500 684 758
16.	Group conversions		
17.	Interest and adjustments on contract or deposit-type contract funds	17,022,504	20,335,674
18.	Payments on supplementary contracts with life contingencies	8,976,427	7,838,717
19.	Increase in aggregate reserves for life and accident and health contracts	1,697,817,747	3,731,008,167
20.	Totals (Lines 10 to 19)	2,608,550,128	4,438,151,022
21.	Commissions on premiums, annuity considerations, and deposit-type contract funds (direct business only) (Exhibit 1, Part 2, Line 31, Col. 1)	658.551 984	497,997,472
22.	Commissions and expense allowances on reinsurance assumed (Exhibit 1, Part 2, Line 26.2, Col. 1)	689,230	311,053
23.	General insurance expenses (Exhibit 2, Line 10, Cols. 1, 2, 3 and 4)	274,366,758	260,757,208
24.	Insurance taxes, licenses and fees, excluding federal income taxes (Exhibit 3, Line 7, Cols. 1 + 2 + 3)	5,483,850	
25.	Increase in loading on deferred and uncollected premiums	2	40E 600 060
26. 27.	Net transfers to or (from) Separate Accounts net of reinsurance	60,951,265	435,692,868 59,331,138
28.	Totals (Lines 20 to 27)	4,073,485,768	5,739,307,090
29.	Net gain from operations before dividends to policyholders and federal income taxes (Line 9 minus Line 28)		226,911,746
30.	Dividends to policyholders		3
31.	Net gain from operations after dividends to policyholders and before federal income taxes (Line 29 minus Line 30)	172,462,504	226,911,743
32.	Federal and foreign income taxes incurred (excluding tax on capital gains)	19,768,341	(73, 122, 463)
33.	Net gain from operations after dividends to policyholders and federal income taxes and before realized capital gains or	150 004 100	000 004 000
0.4	(losses) (Line 31 minus Line 32)	152,694,163	300,034,206
34.	Net realized capital gains (losses) (excluding gains (losses) transferred to the IMR) less capital gains tax of \$38,265,536 (excluding taxes of \$10,946,217 transferred to the IMR)	(72,058,940)	(60,703,393)
35.	Net income (Line 33 plus Line 34)		239,330,813
00.	CAPITAL AND SURPLUS ACCOUNT		200,000,0.0
36.	Capital and surplus, December 31, prior year (Page 3, Line 38, Col. 2)	1,164,208,655	1,113,339,043
	Net income (Line 35)	80,635,223	239,330,813
38.	Change in net unrealized capital gains (losses) less capital gains tax of \$16,761,743	75,011,017	73,359,951
39.	Change in net unrealized foreign exchange capital gain (loss)	4,443,959	
40. 41.	Change in net deferred income tax	(201 140)	(30,007,213 <i>)</i> 1 518 180
42.	Change in liability for reinsurance in unauthorized and certified companies		
43.	Change in reserve on account of change in valuation basis, (increase) or decrease		
44.	Change in asset valuation reserve		
45.	Change in treasury stock (Page 3, Lines 36.1 and 36.2, Col. 2 minus Col. 1)		
46.	Surplus (contributed to) withdrawn from Separate Accounts during period	(173,783,018)	
47.	Other changes in surplus in Separate Accounts Statement		
48. 49.	Change in surplus notes		
50.	Capital changes:		
	50.1 Paid in		
	50.2 Transferred from surplus (Stock Dividend)		
	50.3 Transferred to surplus		
51.	Surplus adjustment: 51.1 Paid in	24 072 019	(1 /8/ 660 601)
	51.2 Transferred to capital (Stock Dividend)		
	51.3 Transferred from capital		
	51.4 Change in surplus as a result of reinsurance		
52.	Dividends to stockholders		
53.	Aggregate write-ins for gains and losses in surplus	(53, 149, 446)	1,513,389,143
	Net change in capital and surplus for the year (Lines 37 through 53)	69,955,168	50,869,613
55.	Capital and surplus, December 31, current year (Lines 36 + 54) (Page 3, Line 38)	1,234,163,823	1,164,208,655
U8 3U1	DETAILS OF WRITE-INS COLI Income	15 120 314	23,371,216
	Miscellaneous (Expense) Income		
	TOOTHANDOO (EAPONDO) THOUMS		
08.398.	Summary of remaining write-ins for Line 8.3 from overflow page		
08.399.	Totals (Lines 08.301 thru 08.303 plus 08.398)(Line 8.3 above)	14,969,049	23,426,162
2701.	Funds Withheld Adjustment - Ceded		
	Transfer to IMR - Ceded		(22,285,349) (1,612,390)
	Summary of remaining write-ins for Line 27 from overflow page		69,656
2799	Totals (Lines 2701 thru 2703 plus 2798)(Line 27 above)	60,951,265	59,331,138
5301.	Correction of Prior Period Error		
	Athene Re IV Tax Sharing Agreement		(518,917)
	SSAP 72 Surplus Reset		1,502,315,641
	Summary of remaining write-ins for Line 53 from overflow page		
5399.	Totals (Lines 5301 thru 5303 plus 5398)(Line 53 above)	(53, 149, 446)	1,513,389,143

		1	2
		Current Year	Prior Year
1.	Cash from Operations Premiums collected net of reinsurance	1 275 400 217	1,537,915,221
2.	Net investment income		2,724,388,270
3.	Miscellaneous income		682,722,828
4.	Total (Lines 1 through 3)		4,945,026,319
5.	Benefit and loss related payments		(216,701,576
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		502,583,845
7.	Commissions, expenses paid and aggregate write-ins for deductions		789 , 165 , 162
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$15,919,911 tax on capital gains (losses)		(79,384,578
10.	Total (Lines 5 through 9)		995,662,85
11.	Net cash from operations (Line 4 minus Line 10)		3,949,363,46
10	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid: 12.1 Bonds	7,330,905,730	6 949 580 16
	12.2 Stocks		
	12.3 Mortgage loans		
	12.4 Real estate		8,291,99
	12.5 Other invested assets		202,331,58
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		57,773,40
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		8,534,655,48
13.	Cost of investments acquired (long-term only):		
10.	13.1 Bonds	6,960,019,372	9 393 177 49
	13.2 Stocks		
	13.3 Mortgage loans	, , , , ,	, ,
	13.4 Real estate		1,744,720,00
	13.5 Other invested assets	447 500 040	
	13.6 Miscellaneous applications		101,338,57
	13.7 Total investments acquired (Lines 13.1 to 13.6)		11,797,391,93
14.	Net increase (decrease) in contract loans and premium notes		(22,853,74
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)		(3,239,882,71
16.	Cash from Financing and Miscellaneous Sources Cash provided (applied):		
10.	16.1 Surplus notes, capital notes		
	16.2 Capital and paid in surplus, less treasury stock		
	- Capital and part in Surprise, issue a south of the surprise and the surp		
	16.3 Borrowed funds		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(86,224,034)	(98,774,50
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(86,224,034)	(98,774,50
17.	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420)	
17.	16.4 Net deposits on deposit-type contracts and other insurance liabilities 16.5 Dividends to stockholders 16.6 Other cash provided (applied)	(1,380,786,420)	(98,774,50
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420)	(98,774,50 837,476,49 738,701,99
18.	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420)	(98,774,50 837,476,49 738,701,99
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323)	837,476,49 738,701,99
18.	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323)	(98,774,50 837,476,498 738,701,993 1,448,182,748 1,727,917,47
18.	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323)	837,476,49 738,701,99
18. 19. ote: Su	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897	1,448,182,74 1,727,917,47 3,176,100,22
18. 19. ote: Su	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897	1,448,182,74 1,727,917,47 3,176,100,22
18. 19. ote: Su 0.0001 0.0002 0.0003	16.4 Net deposits on deposit-type contracts and other insurance liabilities 16.5 Dividends to stockholders 16.6 Other cash provided (applied) Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6) RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) Cash, cash equivalents and short-term investments: 19.1 Beginning of year 19.2 End of year (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 1. Capital contribution of stock compensation expense (financing) 2. Capital contribution of stock compensation expense (investing) 3. Capital contribution of stock compensation expense (operating)	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897 (691,949) (8,380,969)	1,448,182,74 1,727,917,47 3,176,100,22
18. 19. ote: Su 0.0001 0.0002 0.0003	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897 9,072,918 (691,949) (8,380,969) 372,176,281	1,448,182,74 1,727,917,47 3,176,100,22 17,646,04 (1,494,45 (16,151,58 410,513,57
18. 19. 19. 19. 19. 19. 19. 19. 19. 19. 19	16.4 Net deposits on deposit-type contracts and other insurance liabilities 16.5 Dividends to stockholders 16.6 Other cash provided (applied) Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6) RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) Cash, cash equivalents and short-term investments: 19.1 Beginning of year 19.2 End of year (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 1. Capital contribution of stock compensation expense (financing) 2. Capital contribution of stock compensation expense (investing) 3. Capital contribution of stock compensation expense (operating) 4. Reinsurance activity settled in bonds (operating) 5. Reinsurance activity settled in bonds (investing) 6. Security exchanges and asset in kind trades – bond proceeds (investing)	(1,380,786,420) (1,467,010,454) (1,467,010,454) (1,731,847,323) 3,176,100,220 1,444,252,897 (691,949) (8,380,969) 372,176,281 (372,176,281) 1,156,632,177	1,448,182,74 1,727,917,47 3,176,100,22 17,646,04 (1,494,45 (16,151,58 410,513,57 (410,513,57
18. 19. 10. 119.	16.4 Net deposits on deposit-type contracts and other insurance liabilities 16.5 Dividends to stockholders 16.6 Other cash provided (applied) Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6) RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) Cash, cash equivalents and short-term investments: 19.1 Beginning of year 19.2 End of year (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 1. Capital contribution of stock compensation expense (financing) 2. Capital contribution of stock compensation expense (investing) 3. Capital contribution of stock compensation expense (operating) 4. Reinsurance activity settled in bonds (operating) 5. Reinsurance activity settled in bonds (investing) 6. Security exchanges and asset in kind trades – bonds acquired (investing) 7. Security exchanges and asset in kind trades – bonds acquired (investing)	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897 (691,949) (8,380,969) 372,176,281 (372,176,281) 1,156,632,177 (950,199,668)	1,448,182,74 1,448,182,74 1,727,917,47 3,176,100,22 17,646,04 (1,494,45 (16,151,58 410,513,57 (410,513,57 (426,342,44 (426,342,44
18. 19. 19. 10.0001 0.0002 0.0002 0.0006 0.0006 0.0006 0.0006 0.0006	16.4 Net deposits on deposit-type contracts and other insurance liabilities 16.5 Dividends to stockholders 16.6 Other cash provided (applied) Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6) RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17) Cash, cash equivalents and short-term investments: 19.1 Beginning of year 19.2 End of year (Line 18 plus Line 19.1) upplemental disclosures of cash flow information for non-cash transactions: 1. Capital contribution of stock compensation expense (financing) 2. Capital contribution of stock compensation expense (investing) 3. Capital contribution of stock compensation expense (investing) 4. Reinsurance activity settled in bonds (operating) 5. Reinsurance activity settled in bonds (investing) 6. Security exchanges and asset in kind trades – bonds acquired (investing) 7. Security exchanges and asset in kind trades – bonds acquired (investing) 8. Security exchanges and asset in kind trades – bonds acquired (investing) 9. Security exchanges and asset in kind trades – other invested assets acquired (investing) 9. Security exchanges and asset in kind trades – other invested assets acquired (investing)	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897 9,072,918 (691,949) (8,380,969) 372,176,281 (372,176,281) 1,156,632,177 (950,199,668) (153,616,009) (52,816,500)	1,448,182,74 1,448,182,74 1,727,917,47 3,176,100,22
18. 19. 0.0001 0.0002 0.0003 0.0004 0.0006 0.0006 0.0006	16.4 Net deposits on deposit-type contracts and other insurance liabilities	(1,380,786,420) (1,467,010,454) (1,731,847,323) (1,731,847,323) 3,176,100,220 1,444,252,897 9,072,918 (691,949) (8,380,969) 372,176,281 (372,176,281) 1,156,632,177 (950,199,668) (153,616,009) (52,816,500) 17,710,008	1,448,182,74 1,727,917,47 3,176,100,22

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0014. Interest capitalization (operating)	7,755,617	7,681,611
20.0015. Interest capitalization (investing)		
20.0016. Transfer from Schedule B to Schedule BA - proceeds (investing)	94,300	
20.0017. Transfer from Schedule B to Schedule BA - acquired (investing)	(94,300)	
20.0018. Capital contribution (financing)	15,000,000	
20.0019. Capital contribution - stocks acquired (investing)		
20.0020. Transfer from Schedule B to Schedule A - proceeds (investing)		15,627,634
20.0021. Transfer from Schedule B to Schedule A - acquired (investing)		(15,627,634)
20.0022. Transfer from Schedule D to Schedule BA - proceeds (investing)		
20.0023. Transfer from Schedule D to Schedule BA - acquired (investing)		(134,033,354)

Note 1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of **Athene Annuity and Life Company** (the Company) have been prepared in conformity with the accounting practices prescribed or permitted by the National Association of Insurance Commissioners (NAIC) and the State of Iowa.

The Insurance Division, Department of Commerce, of the State of Iowa (the Division) recognizes only statutory accounting practices prescribed or permitted by the State of Iowa for determining and reporting the financial condition and results of operations of an insurance company and for determining its solvency under the Iowa Insurance Law. The NAIC's Accounting Practices & Procedures Manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Iowa. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices.

Among the products issued by the Company are indexed universal life insurance and indexed annuities. These products allow a portion of the premium to earn interest based on certain indices, primarily the Standard & Poor's 500 Composite Stock Price Index. Call options, futures, variance swaps and total return swaps are purchased to hedge the growth in interest credited to the customer as a direct result of increases in the related indices. In 2006, the Commissioner of the Division issued Bulletin 06-01, *Accounting for Derivative Instruments Used to Hedge the Growth in Interest Credited for Index Products*, which prescribes that an insurer may elect to recognize changes in the fair value of derivative instruments purchased to hedge indexed products in the statement of operations. The Company has elected to apply Bulletin 06-01 to its futures, variance swaps and total return swaps, which resulted in a decrease of \$1.5 million and less than \$0.1 million to the Company's net income for the years ended December 31, 2018 and 2017, respectively. Application of Bulletin 06-01 does not impact the Company's statutory surplus amounts.

In 2009, the Commissioner of the Division promulgated Iowa Administrative Code (IAC) Section 191-97, Accounting for Certain Derivative Instruments Used to Hedge the Growth in Interest Credited for Indexed Insurance Products and Accounting for the Indexed Insurance Products Reserve, which prescribes that an insurer may elect (i) to use an amortized cost method to account for certain derivative instruments, such as call options, purchased to hedge the growth in interest credited to the customer on indexed insurance products and (ii) to utilize an indexed annuity reserve calculation methodology under which call options associated with the current index interest crediting term are valued at zero. The Company has elected to apply IAC Section 191-97 to its over the counter (OTC) call options and reserve liabilities. As a result, the Company's net income decreased by \$182.3 million and increased by \$97.2 million for the years ended December 31, 2018 and 2017, respectively, and the Company's statutory surplus increased by \$38.7 million and decreased by \$66.2 million as of December 31, 2018 and 2017, respectively.

The NAIC requires annuities issued by life insurance companies on or after January 1, 2015, to use the 2012 Individual Annuity Reserving (IAR) Mortality Table. In 2015, the Division promulgated IAC Section 43.3(5), which set an elective alternative effective date of January 1, 2016 for adoption of the 2012 IAR Mortality Table. The Company chose to use the Annuity 2000 Mortality Table for all annuities issued in 2015, which resulted in an increase of \$0.6 million and \$1.2 million to the Company's net income for the years ended December 31, 2018 and 2017, respectively. The Company's statutory surplus increased by \$3.3 million and \$2.7 million as of December 31, 2018 and 2017, respectively.

The Company received a permitted practice from the Division which allowed the Company to record a surplus reset under SSAP No. 72, *Surplus and Quasi-Reorganizations*, during the quarter ended March 31, 2017. This approval is deemed a permitted practice as it was granted greater than six months following a change of control, which is the criteria outlined in SSAP No. 72. The acquisition of the Company by Athene Holding Ltd (AHL) on October 2, 2013 represented a 100% change of ultimate ownership as well as a substantive change in the operations of the Company. The surplus reset resulted in a reclassification between unassigned surplus and gross paid-in and contributed surplus of \$1,502.3 million, which is equal to the negative unassigned surplus balance on October 2, 2013 immediately following the execution of all transactions which occurred as a result of the change in control. This permitted practice has no impact on the Company's net income or total capital and surplus.

A reconciliation of the Company's net income and statutory surplus between practices prescribed or permitted by the State of Iowa and NAIC SAP is shown below:

	SSAP _ #	F/S Page	F/S Line #	2018	2017
NET IN	COME				
(1)	State basis (Page 4, Line 35, Columns 1 & 2)	XXX	XXX	80,635,223	239,330,813
(2)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:				
	Derivative Instruments Bulletin 06-0186	4	38	(1,482,864)	(30,784)
	Derivative Instruments and Equity Indexed Reserves IAC 191-9786, 51	2, 3	7, 1	(182,324,925)	97,182,368
	2012 IAR Mortality Table for Annuities Issued in 2015 IAC 43.3(5)51	3	1	604,857	1,180,426
(3)	State Permitted Practices that are an increase/(decrease) from NAIC SAP:				
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	263,838,155	140,998,803
SURPI	LUS				
(5)	State basis (Page 3, Line 38, Columns 1 & 2)	XXX	XXX	1,234,163,823	1,164,208,655
(6)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:				
	Derivative Instruments and Equity Indexed Reserves IAC 191-9786, 51	2, 3	7, 1	38,699,504	(66,192,009)
	2012 IAR Mortality Table for Annuities Issued in 2015 IAC 43.3(5)51	3	1	3,279,539	2,674,683
(7)	State Permitted Practices that are an increase/(decrease) from NAIC SAP: SSAP No. 72 Surplus Reset72	3	33, 35	0	0
(8)	NAIC SAP (5-6-7=8)				

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with NAIC SAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

C. Accounting Policy

Life premiums are recognized as income over the premium paying period of the related policies. Annuity considerations are recognized as revenue when received. Accident and health premiums are earned ratably over the terms of the related insurance and reinsurance contracts or policies. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred.

The amount of dividends to be paid to policyholders is determined annually by the Company's Board of Directors. The aggregate amount of policyholders' dividends is related to actual interest, mortality, morbidity, and expense experience for the year and to the appropriate level of statutory surplus to be retained by the Company.

In addition, the Company uses the following accounting policies, as applicable:

- (1) Short-term investments are stated at amortized cost.
- (2) Bonds, other than loan-backed and structured securities, are stated at amortized cost or fair value based on their rating by the NAIC. Bonds held at amortized cost are amortized using the scientific interest method on a yield-to-worst basis.
- (3) Common stocks are stated at market value except that investments in stocks of subsidiaries and affiliates in which the Company has an interest of 20% or more are carried on the equity basis. Federal Home Loan Bank (FHLB) stock is carried at fair value, which is presumed to be par because it can only be redeemed by the bank.
- (4) Preferred stocks are stated in accordance with the guidance provided in SSAP No. 32, Preferred Stock.
- (5) Mortgage loans on real estate are stated at amortized cost.
- (6) Loan-backed and structured securities are stated at amortized cost or fair market value based on their rating by the NAIC. Changes to estimated cash flows on the securities are accounted for retrospectively for securities that are highly rated at the time of purchase and in which the security cannot be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. The prospective method is used for those securities where an other than temporary impairment has been taken, the security is not highly rated at the time of purchase, securities where receipt of all contractual principal cash flows is not expected, or those securities that can be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. Loan-backed and structured securities stated at amortized cost are amortized or accreted using the scientific interest method.
- (7) The Company carries investments in affiliated common stocks directly and indirectly owned at Statutory (insurance companies) or GAAP (non-insurance companies) net worth plus unamortized goodwill, if applicable, multiplied by the percent of the Company's ownership interest.
- (8) Investments in joint ventures, partnerships, or limited liability companies are valued at the US GAAP equity of the entity, adjusted for audited results upon receipt. Changes in US GAAP equity are recorded as an unrealized gain or loss in the Company's capital and surplus. These investments are valued based on the timeliness of information received, which ranges from recording timely to a lag of up to three months.
- (9) Call option derivative assets that hedge the growth in interest credited to the hedged policy as a direct result of changes in the related indices are recorded at amortized cost. Replication synthetic asset transactions are reported at amortized cost. Derivative instruments used in hedging transactions that meet the criteria of a highly effective hedge shall be considered an effective hedge and are permitted to be valued and reported in a manner that is consistent with the hedged items. All other derivative assets and liabilities are stated at fair value.
- (10) The Company does not anticipate investment income as a factor in the premium deficiency calculation for either life or accident and health business
- (11) Unpaid losses and loss adjustment expenses on any accident and health business include an amount determined from individual case estimates and loss reports and an amount, based on past experience, for losses incurred but not reported. Such liabilities are necessarily based on assumptions and estimates. While management believes the amount is adequate, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liability are periodically reviewed and any adjustment is reflected in the period determined.
- (12) The Company has not modified its capitalization policy from the prior period.
- (13) The Company does not have any pharmaceutical rebate receivables.
- D. Going Concern

Management's assessment of the relevant conditions through February 27, 2019 does not give rise to substantial doubt of the Company's ability to continue as a going concern.

Note 2. Accounting Changes and Corrections of Errors

During the current year's financial statement preparation, the Company discovered errors within prior period Annual Statements relating to A-791 amortization and reserves. After consideration of materiality and in accordance with SSAP No. 3, *Accounting Changes and Correction of Errors*, these corrections were recorded directly to surplus. The impact of the correction of A-791 amortization represented a reclassification of \$54.8 million between income and surplus, with no net impact to surplus, and the impact of the correction of reserves increased surplus by \$0.5 million in 2018. The impact of these amounts represented less than 1% of ending capital and surplus as of both December 31, 2018 and 2017.

Note 3. Business Combinations and Goodwill

A. On October 2, 2013, Athene Annuity & Life Assurance Company (AADE) contributed Athene Annuity & Life Assurance Company of New York (AANY), a New York insurance company, to the Company, which included remaining unamortized goodwill of \$10.7 million. The Company maintained AADE's original goodwill amortization schedule.

1					6	7
	2	3	4	5	Amount of	Admitted
					Goodwill	Goodwill as a %
			Original Amount	Admitted	Amortized During	of SCA BACV,
	Acquisition	Cost of	of Admitted	Goodwill as of the	the	Gross of Admitted
Purchased Entity	Date	Acquired Entity	Goodwill	Reporting Date	Reporting Period	Goodwill
Athene Annuity & Life Assurance						
Company of New York	10/02/2013	193,313,705	10,649,373	4,259,749	1,064,937	1.5%

B. Statutory Merger: NONE

C. Assumption Reinsurance: NONE

D. Impairment Loss: NONE

Note 4. Discontinued Operations: NONE

Note 5. Investments

- A. Mortgage Loans, including Mezzanine Real Estate Loans
 - (1) The maximum and minimum lending rates for new mortgage loans originated during 2018 were 15.25% and 2.00%, respectively.

- (2) The maximum percentage of any one loan to the value of security at the time of the loan, exclusive of insured or guaranteed or purchase money mortgages was 847.52%.
- (3) Taxes, assessments and any amounts advanced and not included in the mortgage loan total: NONE
- (4) Age analysis of mortgage loans and identification of mortgage loans in which the insurer is a participant or co-lender in a mortgage loan agreement

		Residential		Commercial			
	Farm	Insured	All Other	Insured	All Other	Mezzanine	Total
a. Current Year							
Recorded Investment (All)							
(a) Current			.2,048,676,401		.4,138,583,252	.1,408,560,035	.7,595,819,688
(b) 30 - 59 Days Past Due			69,284,378				69,284,378
(c) 60 - 89 Days Past Due			15,917,434				15,917,434
(d) 90 - 179 Days Past Due			13,215,310				13,215,310
(e) 180+ Days Past Due			15,710,646				15,710,646
2. Accruing Interest 90 - 179 Days Past Due							
(a) Recorded Investment							
(b) Interest Accrued							
3. Accruing Interest 180+ Days Past Due							
(a) Recorded Investment							
(b) Interest Accrued							
4. Interest Reduced							
(a) Recorded Investment							
(b) Number of Loans							
(c) Percent Reduced							
Participant or Co-lender in a Mortgage Loan Agreement							
(a) Recorded Investment							
b. Prior Year							
Recorded Investment							
(a) Current			543,653,618		.3,148,890,654	.1,056,900,553	.4,749,444,825
(b) 30 - 59 Days Past Due			33,448,688				33,448,688
(c) 60 - 89 Days Past Due			15,192,906				15,192,906
(d) 90 - 179 Days Past Due			11,369,727				11,369,727
(e) 180+ Days Past Due			7,949,891				7,949,891
2. Accruing Interest 90 - 179 Days Past Due							
(a) Recorded Investment							
(b) Interest Accrued							
3. Accruing Interest 180+ Days Past Due							
(a) Recorded Investment							
(b) Interest Accrued							
4. Interest Reduced							
(a) Recorded Investment							
(b) Number of Loans							
(c) Percent Reduced							
Participant or Co-lender in a Mortgage Loan Agreement							
(a) Recorded Investment							

- (5) Investment in impaired loans with or without allowance for credit losses and impaired loans subject to a participant or co-lender mortgage loan agreement for which the reporting entity is restricted from unilaterally foreclosing on the mortgage loan: NONE
- (6) Investment in impaired loans average recorded investment, interest income recognized, recorded investment on nonaccrual status and amount of interest income recognized using a cash-basis method of accounting: NONE
- (7) Allowance for Credit Losses

	Current Year	Prior Year
a) Balance at beginning of period	1,099,031	1,079,557
b) Additions charged to operations	408,443	19,474
c) Direct write-downs charged against the allowances		
d) Recoveries of amounts previously charged off	(1,079,557)	
e) Balance at end of period	427,917	1,099,031

- (8) Mortgage loans derecognized as a result of foreclosure: NONE
- (9) The company recognizes interest income on its impaired loans upon receipt.
- B. Debt Restructuring

	Current Year	Prior Year
(1) The total recorded investment in restructured loans, as of year end	8,973,531	10,444,954
(2) The realized capital losses related to these loans		
(3) Total contractual commitments to extend credit to debtors owning receivables whose terms have been modified in troubled debt restructurings		
(4) The Company does not accrue interest income on impaired loans. Net investment income loans only after the payment is received.	reflects interest inc	ome on impaired

- C. Reverse Mortgages: NONE
- D. Loan-Backed Securities
 - (1) Prepayment assumptions for loan-backed bonds and structured securities were obtained from broker dealer survey values or internal estimates.

- (2) No other-than-temporary impairment was recognized on loan-backed securities due to the intent to sell or inability or lack of intent to retain the investment for a period of time sufficient to recover the amortized cost basis.
- (3) Other-than-temporary impairment was recognized on the following loan-backed securities due to the present value of the cash flows expected to be collected being less than the amortized cost basis:

1	2	3	4	5	6	7
'	Book/Adjusted	3	4	3	U	Date of
	Carrying Value		Recognized	Amortized Cost		Financial
	Amortized Cost	Present Value of	J	After Other-Than-		Statement
	Before Current	Projected Cash	Temporary	Temporary	Fair Value at	Where
CUSIP	Period OTTI	Flows	Impairment	Impairment	time of OTTI	Reported
00442B-AE-1						
05946X-QS-5						
36185M-DQ-2						
38375U-TN-0						
38375U-VC-1						
46629C-AA-5						
61748H-RW-3						
94980X-AS-3						
38375B-MA-7						
38375B-KT-8						
38375U-KH-2						
38375U-TL-4						
38375U-ZG-8						
38375B-JP-8						
36185M-DQ-2						
46629C-AA-5						
79548K-ZL-5						
38376R-UM-6						
61762B-AU-9						
61766L-AY-5						
66704J-AC-2						
66704J-AG-3	30,693,315	29,795,063	898,253	29,795,063	29,795,063	09/30/2018
79548K-ZL-5	2,342,261	2,313,890	28,371	2,313,890	2,276,699	09/30/2018
86359L-QS-1						
86359L-QS-1	7,693,141	7,453,790	239,350	7,453,790	7,137,987	12/31/2018
36190D-AD-7	2,392,800	2,250,955	141,845	2,250,955	2,250,955	12/31/2018
79548K-ZL-5	2,193,609	2,122,944	70,665	2,122,944	2,075,917	12/31/2018
61761P-AC-9	2,882,474	2,821,875	60,599	2,821,875	2,855,980	12/31/2018
41161P-LQ-4	3,373,906	3,326,611	47,295	3,326,611	3,220,387	12/31/2018
05946X-QS-5						
61756V-BE-8	4,682,822	4,649,538	33,284	4,649,538	4,537,182	12/31/2018
05950P-AF-0						
41161G-AC-7	1,804,265	1,777,600	26,665	1,777,600	1,747,755	12/31/2018
61690T-AH-6						
Total	XXX	XXX	2,855,210	XXX	XXX	XXX

- (4) The following table shows the gross unrealized losses and fair values of loan-backed securities, which have not been impaired to fair value, aggregated by length of time that individual securities have been in a continuous unrealized loss position as of December 31, 2018.
 - a. The aggregate amount of unrealized losses:
 - 1. Less than 12 Months212,928,2312. 12 Months or Longer48,103,676b. The aggregate related fair value of securities with unrealized losses:
 - 1. Less than 12 Months
 5,103,903,561

 2. 12 Months or Longer
 994,103,628
- (5) A full analysis of all relevant qualitative considerations was completed in reaching the conclusion that the impairments were not other-thantemporary, including the intent and ability to hold the investment for a period of time sufficient to allow for a recovery in value. Specific events that may influence the operations of the issuer and impaired earnings potential are reviewed in addition to length of time and extent to which the fair value has been less than cost.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions: NONE
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing: NONE
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing: NONE
- H. Repurchase Agreements Transactions Accounted for as a Sale: NONE
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale: NONE
- J. Real Estate
 - (1) Impairment Loss: NONE
 - (2) During 2018, the Company sold its Cedar Valley, REO and AREI (Interpark), LLC real estate held on Schedule A for cumulative proceeds of \$9.9 million. A loss of \$0.2 million was recognized as a result of the sales. The loss is aggregated within Net Realized Capital Gains (Losses) in the Summary of Operations Line 34.
 - (3) Changes to Plan of Sale: NONE
 - (4) Retail Land Sales: NONE
 - (5) Participating Mortgage Loan Features: NONE
- K. Low-Income Housing Tax Credits: NONE

Restricted Assets

(1) Restricted assets (including pledged)

	Gross (Admitted & Nonadmitted) Restricted						
			Current Year		,	6	7
	1	2	3	4	5		
Restricted Asset Category	Total General Account (G/A)	G/A Supporting Separate Account (S/A) Activity (a)	Total S/A Restricted Assets	S/A Assets Supporting G/A Activity (b)	Total (1 plus 3)	Total From Prior Year	Increase/ (Decrease) (5 minus 6)
a. Subject to contractual obligation for which liability is not shown							
b. Collateral held under security lending agreements							
c. Subject to repurchase agreements							
d. Subject to reverse repurchase agreements							
e. Subject to dollar repurchase agreements							
f. Subject to dollar reverse repurchase agreements							
g. Placed under option contracts							
h. Letter stock or securities restricted as to sale - excluding FHLB capital stock							
i. FHLB capital stock							
j. On deposit with states	6,661,724				6,661,724	6,730,298	(68,574)
k. On deposit with other regulatory bodies							
Pledged collateral to FHLB (including assets backing funding agreements)	. 1,220,540,486	. 1,220,540,486			.1,220,540,486	903,780,228	316,760,258
m. Pledged as collateral not captured in other categories	113,930,723				113,930,723	153,906,641	(39,975,918)
n. Other restricted assets	6,641,854				6,641,854	8,464,935	(1,823,081)
o. Total Restricted Assets	. 1,394,822,787	. 1,220,540,486			.1,394,822,787	.1,104,786,102	290,036,685

⁽a) Subset of Column 1

⁽b) Subset of Column 3

		Current Year						
		8	9		entage			
				10				
				Gross	11 Admitted			
				(Admitted & Nonadmitted)	Restricted to			
		Total	Total Admitted	Restricted to	Total Admitted			
		Nonadmitted	Restricted	Total Assets	Assets			
Restricted Asse	t Category	Restricted	(5 minus 8)	(c)	(d)			
a. Subject to contractual ol	oligation for which							
liability is not shown				0.000	0.000			
b. Collateral held under se	curity lending							
agreements				0.000	0.000			
c. Subject to repurchase a	greements			0.000	0.000			
d. Subject to reverse repur								
				0.000	0.000			
e. Subject to dollar repurch	nase agreements			0.000	0.000			
f. Subject to dollar reverse	repurchase							
agreements				0.000	0.000			
g. Placed under option cor	tracts			0.000	0.000			
h. Letter stock or securities	restricted as to							
sale - excluding FHLB	capital stock			0.000	0.000			
i. FHLB capital stock			47,048,000	0.081	0.081			
j. On deposit with states			6,661,724	0.011	0.011			
k. On deposit with other re	gulatory bodies			0.000	0.000			
I. Pledged collateral to FH								
assets backing funding	agreements)		. 1,220,540,486	2.104	2.104			
m. Pledged as collateral no								
categories			113,930,723	0.196	0.196			
n. Other restricted assets .			6,641,854	0.011	0.011			
o. Total Restricted Assets								
() 0 5			1,00 .,022,101					

⁽c) Column 5 divided by Asset Page, Column 1, Line 28 $\,$

(2) Detail of assets pledged as collateral not captured in other categories (contracts that share similar characteristics, such as reinsurance and derivatives, are reported in the aggregate)

		(Gross (Admit		8	Perce	entage			
			Current Yea	ır		6	7		9	10
	1	2	3	4	5					
		G/A Supporting								
		Supporting Separate							Gross	Admitted
		Account		S/A Assets				Total Current	(Admitted &	Restricted to
	Total General	(S/A)	Total S/A	Supporting			Increase/	Year	Nonadmitted)	Total
	Account	Activity	Restricted	G/A Activity	Total	Total From	(Decrease)	Admitted	Restricted to	Admitted
Description of Assets	(G/A)	(a)	Assets	(b)	(1 plus 3)	Prior Year	(5 minus 6)	Restricted	Total Assets	Assets
Reinsurance trusts	71,694,146				71,694,146	72,083,412	(389,266)	71,694,146	0.124	0.124
Derivative collateral asset	42,236,577				42,236,577	81,823,229	(39,586,652)	42,236,577	0.073	0.073
Total (c)	.113,930,723				.113,930,723	153,906,641	(39,975,918)	113,930,723	0.196	0.196

⁽a) Subset of column 1 (b) Subset of column 3

⁽d) Column 9 divided by Asset Page, Column 3, Line 28 $\,$

⁽c) Total Line for Columns 1 through 7 should equal 5L(1)m Columns 1 through 7 respectively and Total Line for Columns 8 through 10 should equal 5L(1)m Columns 9 through 11 respectively.

(3) Detail of other restricted assets (contracts that share similar characteristics, such as reinsurance and derivatives, are reported in the aggregate)

	Gross (Admitted & Nonadmitted) Restricted							8	Perce	ntage
		Current Year				6	7		9	10
	1	2	3	4	5					
		G/A								
		Supporting								
		Separate							Gross	Admitted
		Account		S/A Assets				Total Current	(Admitted &	Restricted to
	Total General	(S/A)	Total S/A	Supporting			Increase/	Year	Nonadmitted)	Total
	Account	Activity	Restricted	G/A Activity	Total	Total From	(Decrease)	Admitted	Restricted to	Admitted
Description of Assets	(G/A)	(a)	Assets	(b)	(1 plus 3)	Prior Year	(5 minus 6)	Restricted	Total Assets	Assets
Commercial mortgages	6,641,854				6,641,854	8,464,935	(1,823,081)	6,641,854	0.011	0.011
Total (c)	6,641,854				6,641,854	8,464,935	(1,823,081)	6,641,854	0.011	0.011

⁽a) Subset of column 1

(4) Collateral received and reflected as assets within the reporting entity's financial statements

	1	2	3	4
	·	-	% of BACV to	·
	Book/Adjusted		Total Assets	% of BACV to
	Carrying Value		(Admitted and	Total Admitted Assets
Collateral Assets	(BACV)	Fair Value	Nonadmitted)*	**
a. Cash, Cash Equivalents and Short-Term				
Investments	875,837,195	875,837,195	1.653	%1.654 %
b. Schedule D, Part 1				
c. Schedule D, Part 2, Section 1			0.000	%0.000 %
d. Schedule D, Part 2, Section 2			0.000	%0.000 %
e. Schedule B			0.000	%0.000 %
f. Schedule A			0.000	%0.000 %
g. Schedule BA, Part 1			0.000	%0.000 %
h. Schedule DL, Part 1			0.000	%0.000 %
i. Other			0.000	%0.000 %
j. Total Collateral Assets (a+b+c+d+e+f+g+h+i)	875,837,195	875,837,195	1.653	%

^{*} Column 1 divided by Asset Page, Line 26 (Column 1)

^{**} Column 1 divided by Asset Page, Line 26 (Column 3)

	1	2	
		% of Liability to Tota	ıl
	Amount	Liabilities *	
. Recognized Obligation to Return Collateral Asset	875.837.195	1.683	%

^{*} Column 1 divided by Liability Page, Line 26 (Column 1)

M. Working Capital Finance Investments: NONE

N. Offsetting and Netting of Assets and Liabilities: NONE

O. Structured Notes: NONE

P. 5GI Securities

Investment	Number of 5	GI Securities	Aggrega	te BACV	Aggregate Fair Value		
	Current Year Prior Year		Current Year	Prior Year	Current Year	Prior Year	
(1) Bonds - AC	1	1	11,731,254	11,036,690	11,385,565	11,036,690	
(2) LB&SS - AC	4	6	1,568,113	6,011,198	1,938,144	6,417,518	
(3) Preferred Stock - AC							
(4) Preferred Stock - FV							
(5) Total (1+2+3+4)				17,047,888	13,323,709	17,454,208	

AC - Amortized Cost FV - Fair Value

Q. Short Sales: NONE

R. Prepayment Penalty and Acceleration Fees

	General Account	Separate Account
1. Number of CUSIPs	50	2
2. Aggregate Amount of Investment Income	21,535,093	448,300

Note 6. Joint Ventures, Partnerships and Limited Liability Companies

- A. The Company has no investments in Joint Venture, Partnerships or Limited Liability Companies representing more than 10% of its admitted assets.
- 3. The Company recognized other-than-temporary impairments of \$45.4 million and \$1.1 million as of December 31, 2018 and 2017, respectively, on partnerships and limited liability companies included in Schedule BA. The impairments were based on an assessment that future cash flows of affected limited partnerships would be less than the cost basis of the limited partnership. Fair value is determined by statements received from the partnerships and limited liability companies.

Note 7. Investment Income

- A. Due and accrued income was excluded from surplus on the following basis: All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default.
- B. The total amount excluded was \$0.4 million and \$0.1 million as of December 31, 2018 and 2017, respectively.

⁽b) Subset of column 3

⁽c) Total Line for Columns 1 through 7 should equal 5L(1)n Columns 1 through 7 respectively and Total Line for Columns 8 through 10 should equal 5L(1)n Columns 9 through 11 respectively.

Note 8. Derivative Instruments

A, B, C. The Company utilizes derivative instruments which may include the following:

Options: The Company has issued fixed indexed products. These contracts credit interest based on certain indices, primarily the Standard & Poor's 500® Composite Stock Price Index. Over-the-counter (OTC) option contracts, call options and call spreads are purchased to hedge the growth in interest credited to the customer as a direct result of increases in the related indices. Upon exercise, the Company will receive the fair value of the call option. The parties with whom the Company enters into OTC option contracts are highly rated financial institutions where contracts are supported by collateral, which minimizes the credit risk associated with such contracts.

Variance Swaps: The Company has issued fixed indexed products. These contracts credit interest based on certain indices, primarily the Standard & Poor's 500® Composite Stock Price Index. The Company uses variance swaps to hedge the market risks from changes in volatility for these products. Under variance swaps, the Company and the counterparty agree to exchange amounts calculated based on a fixed rate (implied volatility at inception of transaction) and realized volatility over the life of the transaction (similar to an interest rate swap). Generally, no cash is exchanged at the outset of the contract and neither party makes principal payments. The parties with whom the Company enters into OTC variance swaps contracts are highly rated financial institutions which minimizes the credit risk associated with such contracts.

Interest Rate Swaps: The Company uses interest rate swaps to reduce market risks from changes in interest rates and to alter interest rate exposure arising from mismatches between assets and liabilities. Under interest rate swaps, the Company agrees with other parties to exchange, at specified intervals, the difference between fixed-rate and floating-rate interest amounts calculated by reference to an agreed notional principal amount. Generally, no cash is exchanged at the outset of the contract and neither party makes principal payments.

The interest rate swaps that qualify for hedge accounting in accordance SSAP No. 86, *Derivatives*, are recorded in a manner consistent with the hedged asset or liability. Qualifying interest rate swaps hedging liabilities, are carried at amortized cost. Cash which is exchanged as the difference between fixed and floating interest rates is recognized in the statements of operations through investment income. If the contract is terminated prior to maturity, a realized gain or loss is reported in the statements of operations for the amount of cash exchanged in order to close the contract.

Futures: Under exchange-traded futures contracts, the Company agrees to purchase a specified number of contracts with other parties and to post variation margin on a daily basis in an amount equal to the difference in the daily fair values of those contracts. Futures contracts are purchased to hedge the growth in interest credited to the customer as a direct result of increases in the related indices. The clearing broker with whom the Company enters into exchange-traded futures are regulated futures commission merchants who are members of a trading exchange.

Futures are recorded at fair value of margin on deposit with the clearing broker and changes in this margin on deposit are recognized in the Summary of Operations through investment income.

Currency Swaps: Foreign currency swaps are used by the Company to reduce the risk from fluctuations in foreign currency exchange rates associated with its assets denominated in foreign currencies. With a foreign currency swap transaction, the Company agrees with another party to exchange, at specified intervals, the difference between one currency and another at a forward exchange rate calculated by reference to an agreed upon principal amount. The principal amount of each currency is exchanged at the inception and termination of the currency swap by each party.

The currency swaps that qualify for hedge accounting in accordance with SSAP No. 86 are recorded in a manner consistent with the hedged asset or liability. The change in the value of the hedged item due to fluctuations in foreign exchange rates is recorded as unrealized capital gains or losses until the time of sale. As such, the qualifying currency swap also records the change in value associated with fluctuations in foreign currency exchange rates in unrealized capital gains and losses.

Forwards: The Company uses foreign exchange forward contracts to hedge certain invested assets against movement in foreign currency. The price is agreed upon at the time of the contract and payment for such a contract is made at a specified future date. Foreign exchange forward contracts are utilized in non-qualifying hedging relationships.

Credit Default Swaps: Credit default swaps are used to synthetically create the characteristics of a bond, or hedge credit risk, referred to as a replication synthetic asset transaction (RSAT). An RSAT is created by coupling a bond with a credit default swap to create a synthetic instrument that is cheaper than its cost in the cash market or one which has better default characteristics. These transactions provide the Company with a periodic premium to compensate it for accepting credit risk and are used to enhance investment income and improve the default characteristics of the portfolio. The exposure amount of such agreement, which is usually the notional amount, is equal to the maximum proceeds that must be paid by a counterparty for a defaulted security. Should a credit event occur on a reference entity, a counterparty would be required to pay the notional amount in exchange for receipt of an obligation of the reference entity. Generally, there is no cash requirement at the initiation of the credit default swap contract.

Credit default swaps used in replication transactions are carried at amortized cost. The premiums received are accrued and recognized in the Summary of Operations through investment income over the life of the agreements. A capital loss would be recorded on the date of default, through the Summary of Operations, to reflect the difference between the notional amount paid and the fair value of the bonds received.

Total Return Swaps: The Company purchases total return swaps to gain exposure and benefit from a reference asset without actually having to own it. Total return swaps are contracts in which one party makes payments based on a set rate, either fixed or variable, while the other party makes payments based on the return of the underlying asset, which includes both the income it generates and any capital gains.

See Note 1 for further explanation of the accounting policy for derivatives.

- D. There were no derivative contracts with financing premiums.
- E. There were no gains or losses recognized in unrealized gains or losses during the reporting period representing the component of the derivative instrument's gain or loss excluded from the assessment of hedge effectiveness.
- F. There were no net gains or losses recognized in unrealized gains or losses during the reporting period resulting from derivatives that no longer qualify for hedge accounting.
- G. There are no derivatives accounted for as cash flow hedges of a forecasted transaction.
- H. There were no derivative contracts with premium cost.

Note. 9. Income Taxes

(

A. The components of the net deferred tax asset/(liability) at December 31 are as follows:

(1)											
			12/31/2018			12/31/2017			Change		
		(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	
				(Col. 1 + 2)			(Col. 4 + 5)	(Col. 1 - 4)	(Col. 2 - 5)	(Col. 7 + 8)	
L		Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total	
	(a) Gross Deferred Tax Assets	. 398,428,885		. 398,428,885	398,978,337		. 398,978,337	(549,452)		(549,452)	
	(b) Statutory Valuation Allowance Adjustment										
	(c) Adjusted Gross Deferred Tax Assets (1a - 1b)	. 398,428,885		. 398,428,885	398,978,337		. 398,978,337	(549,452)		(549,452)	
	(d) Deferred Tax Assets Nonadmitted										
	(e) Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	. 398,428,885		. 398,428,885	398,978,337		. 398,978,337	(549,452)		(549,452)	
	(f) Deferred Tax Liabilities	. 366,278,072	12,768,988	. 379,047,060	402,009,205	13,855,372	. 415,864,577	. (35,731,133)	(1,086,384)	.(36,817,517)	
	(g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability)				,						
L	(1e - 1f)	32,150,813	. (12,768,988)	19,381,825	(3,030,868)	. (13,855,372)	.(16,886,240)	35,181,681	1,086,384	36,268,065	

	1	12/31/2018			12/31/2017			Change	
	(4)		(0)	(4)					(0)
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	Ordinary	Capital	(Col. 1 + 2) Total	Ordinary	Capital	(Col. 4 + 5) Total	(Col. 1 - 4) Ordinary	(Col. 2 - 5) Capital	(Col. 7 + 8) Total
Admission Calculation Components				-			•		
SSAP No. 101									
(a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	65,413,221		65,413,221	. 123,464,416		. 123,464,416	(58,051,195)		.(58,051,195)
Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date.	65,413,221		65,413,221	. 123,464,416		. 123,464,416	(58,051,195)		.(58,051,195
Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold	XXX	XXX	182,217,300	XXX	XXX	. 174,631,298	XXX	XXX	7,586,002
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities	. 333,015,664		333,015,664	. 275,513,921		. 275,513,921	57,501,743		57,501,743
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)).	398 428 885		398 428 885	398 978 337		398 978 337	(549 452)		(549 452

(3)		
	2018	2017
Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount.	852.8%	989.0%
Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.	1,886,820,415	1,750,410,547

(4)							
Ì		12/31	/2018	12/31	/2017	Cha	ange
		(1)	(2)	(3)	(4)	(5)	(6)
						(Col. 1 - 3)	(Col. 2 - 4)
		Ordinary	Capital	Ordinary	Capital	Ordinary	Capital
	Impact of Tax Planning Strategies:						
	(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.						
	1. Adjusted Gross DTAs amount from Note 9A1(c)	398,428,885		398,978,337		(549,452)	
	Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	3. Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	398,428,885		398,978,337		(549,452)	
	Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning						
	strategies	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

B. Regarding deferred tax liabilities that are not recognized

No DTLs have been recognized with respect to life insurance policies owned by the Company insuring the lives of certain officers and employees. The Company intends to realize tax-exempt benefits upon the deaths of the insured lives. If, however, the Company surrendered all of the policies prior to the deaths of the insured lives, the Company would incur a tax liability of approximately \$42.2 million on unprovided taxable temporary differences of approximately \$201.1 million.

No unrecognized DTL exists for temporary differences related to investments in foreign subsidiaries or foreign corporate joint ventures that are essentially permanent in duration.

C. Current income taxes incurred consist of the following major components:

	(1)	(2)	(3)
4 Current leasure Teu	40/04/0040	40/04/0047	(Col. 1 - 2)
1. Current Income Tax	12/31/2018 19,768,341	12/31/2017	Change 92.890.804
(a) Federal(b) Foreign	, ,		. , ,
(c) Subtotal			
(d) Federal income tax on net capital gains			
(e) Utilization of capital loss carry-forwards			
(f) Other			
(g) Federal and foreign income taxes incurred	68,980,094	(4,136,468).	73,116,562
2. Deferred Tax Assets:			
(a) Ordinary:			
(1) Discounting of unpaid losses			
(2) Unearned premium reserve			
(3) Policyholder reserves			
(4) Investments			
(5) Deferred acquisition costs			
(7) Fixed Assets			
(8) Compensation and benefits accrual			
(9) Pension accrual			
(10) Receivables - nonadmitted			
(11) Net operating loss carry-forward	3,291	42,327,509.	(42,324,218)
(12) Tax credit carry-forward			
(13) Other (including items <5% of total ordinary tax assets)			
(99) Subtotal			
(b) Statutory valuation allowance adjustment			
(c) Nonadmitted			
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)(e) Capital:	398,428,885	398,978,337	(549,452)
(1) Investments			
(2) Net capital loss carry-forward			
(3) Real estate			
(4) Other (including items <5% of total ordinary tax assets)			
(99) Subtotal			
(f) Statutory valuation allowance adjustment			
(g) Nonadmitted			
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	200 420 005	200 070 227	/E40.4E2
(i) Admitted deletted tax assets (20 + 211)	390,420,003	390,970,337.	(549,452
3. Deferred Tax Liabilities:			
(a) Ordinary:			
(a) Ordinary.			
(1) Investments	117,876,061	119,319,983.	(1,443,922)
(2) Fixed assets			
(3) Deferred and uncollected premium			
(4) Policyholder reserves			
(5) Other (including items <5% of total ordinary tax liabilities)			
(99) Subtotal	366,278,072	402,009,205	(35,731,133)
(b) Capital: (1) Investments	10 760 000	12 055 270	(4.000.004)
(1) Investments			
(2) Real estate			
(99) Subtotal			
(c) Deferred tax liabilities (3a99 + 3b99)			
4. Net deferred tax assets/liabilities (2i - 3c)			
4. Net deferred tax assets/liabilities (2i - 3c)	19,381,825	(16,886,240).	

The change in net deferred taxes is comprised of the following (this analysis is exclusive of the tax effect of unrealized capital gain (losses) as the deferred taxes on unrealized gains (losses) are reported separately from the Change in Net Deferred Income Taxes in the surplus section of the Annual Statement):

Change in Net Deferred Income Tax:

	2018	2017	Change
Adjusted gross deferred tax assets	398,428,885	398,978,337	(549,452)
Total deferred tax liabilities	(379,047,060)	(415,864,577)	36,817,517
Net deferred tax assets (liabilities)	19,381,825	(16,886,240)	36,268,065
Tax effect of unrealized gains (losses)		<u>-</u>	16,761,743
Change in net deferred income tax		_	53,029,808

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. Among the more significant book to tax adjustments were the following:

Reconciliation of Federal Income Tax Rate to Actual Effective Rate:

		Effective Tax
	<u>2018</u>	Rate
Provision computed at statutory rate	\$29,120,511	21.0%
Permanent differences		
IMR	58,383	0.0%
Nontaxable income	(3,175,266)	-2.3%
Nondeductible expenses	887,967	0.6%
Affiliated expenses	(713,206)	-0.5%
Non-admitted assets	(42,239)	0.0%
Specific reserves in surplus	140,934	0.1%
Prior year true-up and adjustments	(4,196,011)	-3.0%
Unrealized gain ceded	(19,435,254)	-13.9%
Reinsurance adjustment A-791	11,054,041	8.0%
Tax rate change	2,250,426	1.6%
Total	\$15,950,286	11.6%
Fadaval and fanaina in annua bassa in assumed	#40.700.044	44.20/
Federal and foreign income taxes incurred	\$19,768,341	14.3%
Realized capital gains (losses) tax	49,211,753	35.5%
Change in net deferred income taxes	(53,029,808)	-38.2%
Total statutory income taxes	\$15,950,286	11.6%

- E. The Company has the following carry forwards at December 31, 2018:
 - (1) The Company has tax attribute carry forwards as follows:

	Operations Lo	ss Deductions
Year Incurred	Amount	Expiring
2013 2nd short period	\$15,671	2033

(2) The amount of capital gains taxes incurred available for recoupment in the event of future capital losses are:

Recovery Year	Recoverable Taxes
2018	\$36,689,176
2017	\$0
2016	\$0

- (3) There are no aggregate amount of deposits reported as admitted assets under Section 6603 of the Internal Revenue Code as of December 31, 2018 and 2017.
- F. The Company files as a member of a consolidated federal income tax return with its parent company, AADE. The Company is a party to a written tax sharing agreement that has been approved by the Board of Directors. Allocation of tax benefits is based on separate returns. Losses are paid at the time they can be used in the consolidated return. Intercompany tax balances are settled quarterly.

The Company has also entered into a supplemental tax sharing agreement with Athene Re USA IV, Inc. (Athene Re IV), whereby the Company is obligated to perform all of Athene Re IV's tax sharing obligations and is entitled to accept all of Athene Re IV's tax sharing benefits. Accordingly, any current taxes payable or receivable by Athene Re IV is reflected by the Company.

The following entities are included in the consolidated return:

Athene Annuity & Life Assurance Company
Athene Annuity and Life Company
Athene Annuity & Life Assurance Company of New York
Athene Life Insurance Company of New York
Structured Annuity Reinsurance Company
Athene Re USA IV, Inc.

G. Federal or Foreign Income Tax Loss Contingencies

The Company does not have any tax loss contingencies for which it is reasonably possible that the total tax liability will significantly increase within 12 months of the reporting date.

Note 10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A, B, C. The Company's various affiliated relationships, agreements and transactions are discussed within Notes 10A through 10F and the 2018 affiliated transactions are disclosed in Schedule Y, part 2.

During February 2018, Athene Life Re Ltd. (ALRe) formed a subsidiary Bermuda reinsurer, Athene Annuity Re Ltd. (AARe) which has been licensed with the Bermuda Monetary Authority. During 2018, pursuant to a Contribution Agreement, AHL contributed Athene USA Corporation, an indirect parent of the Company, and its subsidiaries to AHL's wholly owned subsidiary ALRe.

The Company recaptured, amended, and entered into new reinsurance agreements with affiliates during 2018. See Note 23, Reinsurance for the details of those changes.

The Company cedes a quota share of its annuity business to AARe and AADE, a 100% quota share of its funding agreement business to AARe and 100% of the Closed Block liabilities to Athene Re IV. The Company cedes to Structured Annuity Reinsurance Company a 100% quota share of its benefits payable for all structured annuity contracts issued by the Company to Aviva London Assignment Corporation (an affiliated company prior to October 2, 2013). See disclosures in Schedule S and Schedule Y, part 2.

Some employees of Athene Employee Services LLC participate in one or more Share Award Agreements (the Agreements) sponsored by AHL, an indirect parent of the Company, for which the Company has no legal obligation. Salary expense of Athene Employee Services LLC is partially allocated to the Company through the Shared Services Agreement. Under SSAP No. 104R, Share-Based Payments, the stock compensation expense associated with the Agreements that would have been allocated to the Company is required to be recorded as a capital contribution to the reporting entity. The Company has allocated the stock compensation expense associated with the Agreements based on the same methodology as the Shared Services Agreement. In accordance with SSAP No. 104R, the Company incurred expense and recorded a capital contribution under the Agreements totaling \$9.1 million and \$17.6 million in 2018 and 2017, respectively, which includes amounts contributed by the Company to downstream insurance subsidiaries.

During July 2018, the Company received a \$15.0 million capital contribution from its direct parent, AADE, and the Company made a \$15.0 million capital contribution to its wholly-owned subsidiary, AANY.

- D. As of December 31, 2018 and 2017, respectively, the Company reported \$0.4 million and \$0.3 million receivable due from affiliates and \$14.0 million and \$20.0 million payable due to affiliates. All intercompany balances shown as payable to or receivable from parent, subsidiaries and affiliates are settled within 45 days of their incurrence under the terms of the intercompany expense sharing agreements.
- E. The Company has guaranteed the tenant obligations of a former affiliate, Aviva Investors Americas LLC, under a lease of premises located on the 21st floor of 375 Park Avenue, New York City, as disclosed in Note 14. The Company has been indemnified for any liability relating to this guarantee under the terms of the stock purchase agreement between Aviva plc and AHL. The Company has no exposure associated with this guarantee.
- F. The Company participates in an investment management agreement with Athene Asset Management LLC (AAM), an affiliate, under which AAM has agreed to provide asset management services in exchange for management fees. The Company pays 30 basis points (bps) per annum on the Company's managed assets. The Company incurred AAM investment expenses of \$150.9 million and \$139.0 million in 2018 and 2017, respectively.

The Company participates in a Shared Services and Cost Sharing Agreement with certain other affiliated companies pursuant to which each party thereto agreed to provide certain financial, legal and other services to the other parties. The Company incurred related expenses under these agreements totaling \$236.0 million and \$223.0 million in 2018 and 2017, respectively.

- G. The operating results and financial position of the Company as reported in these financial statements would not be significantly different from those that would have been obtained if the Company were autonomous.
- H. Amounts deducted from the value of an upstream intermediate entity or ultimate parent: NONE
- I. The Company does not hold an investment in a subsidiary, controlled or affiliated company (SCA) that exceeds 10% of admitted assets.
- J. The Company did not recognize any impairment write downs for its investment in SCAs during the statement period.
- K. The Company does not hold an investment in a foreign insurance subsidiary.
- The Company does not hold an investment in a downstream noninsurance holding company.
- M. Subsidiary, Controlled or Affiliated (SCA) Investments
 - (1) Balance sheet value (admitted and nonadmitted) all SCAs (except 8bi entities)

SCA Entity	Percentage of SCA Ownership	Gross Amount	Admitted Amount	Nonadmitted Amount
a. SSAP No. 97 8a Entities				
Total SSAP No. 97 8a Entities	XXX			
b. SSAP No. 97 8b(ii) Entities				
Total SSAP No. 97 8b(ii) Entities	XXX			
c. SSAP No. 97 8b(iii) Entities Centralife Annuities Services, Inc	100.0	0	0	
Total SSAP No. 97 8b(iii) Entities	XXX	0	0	C
d. SSAP No. 97 8b(iv) Entities	1		<u> </u>	
Total SSAP No. 97 8b(iv) Entities	XXX			
e. Total SSAP No. 97 8b Entities (except 8bi entities) (b+c+d)	XXX	0	0	
f. Aggregate Total (a+ e)	XXX	0	0	(

(2) NAIC filing response information

SCA Entity (Should be same entities as shown in M(1) above.)	Type of NAIC Filing	Date of Filing to the NAIC	NAIC Valuation Amount	NAIC Response Received Y/N	NAIC Disallowed Entities Valuation Method, Resub- mission Required Y/N	Code **
a. SSAP No. 97 8a Entities	2007	2007		\/\/\/	2007	2007
Total SSAP No. 97 8a Entities	XXX	XXX		XXX	XXX	XXX
b. SSAP No. 97 8b(ii) Entities						
Total SSAP No. 97 8b(ii) Entities	XXX	XXX		XXX	XXX	XXX
c. SSAP No. 97 8b(iii) Entities Centralife Annuities Services, Inc	S2	10/15/2018 XXX	0	Y	N	N/A
The state of the s						
d. SSAP No. 97 8b(iv) Entities						
Total SSAP No. 97 8b(iv) Entities	XXX	XXX		XXX	XXX	XXX
e. Total SSAP No. 97 8b Entities (except 8bi entities) (b+c+d)	XXX	XXX	0	XXX	XXX	XXX
f. Aggregate Total (a+ e)	XXX	XXX	0	XXX	XXX	XXX

^{*} S1 - Sub-1, S2 - Sub-2 or RDF - Resubmission of Disallowed Filing

N. Investment in Insurance SCAs

The Company owns all of the outstanding capital stock of Athene Re IV, a special purpose financial captive life insurance company domiciled in the State of Vermont.

- Athene Re IV, with the explicit permission of the Commissioner of the Vermont Department of Financial Regulation of the State of Vermont, has included as admitted assets the value of a letter of credit serving as collateral for reinsurance credit taken by the Company in connection with reinsurance agreements entered into between Athene Re IV and the Company. Under NAIC SAP, the letters of credit would not otherwise be treated as admitted assets.
- 2. The monetary effect on net income and surplus as a result of using an accounting practice that differed from NAIC SAP, the amount of the investment in the insurance SCA per audited statutory equity and amount of the investment if the insurance SCA had completed statutory financial statements in accordance with the AP&P Manual is as follows:

	Monetary Effect	t on NAIC SAP	Amount of	Investment
				If the Insurance SCA Had
	Not Income	Cumlus		Completed
SCA Entity	Net Income Increase	Surplus Increase	Per Audited	Statutory Financial
(Investments in Insurance SCA Entities)	(Decrease)	(Decrease)	Statutory Equity	Statements *
Athene Re IV	0	152,500,000	28,814,895	0

^{*} Per AP&P Manual (without permitted or prescribed practices)

As of the issue date of this report, the 2018 statutory audit of Athene Re IV has not been completed.

- If Athene Re IV had not been permitted to include the letter of credit in surplus, its risk-based capital would have been below Mandatory Control Level.
- O. The Company does not hold an investment in a SCA where the Company's share of losses exceeds its investment in the SCA.

Note 11. Debt

A. Athene USA Corporation (AUSA) is the holder of a five-year, Unsecured Revolving Promissory Note dated May 1, 2016 (the Promissory Note) with a maximum principal amount not to exceed \$200,000,000, among AUSA and certain of its subsidiaries, including the Company. The Promissory Note was approved by the lowa Insurance Division. Interest shall accrue on the principal balance from time to time outstanding at a rate per annum equal to 1 month London Interbank Offered Rate + 162.5 bps. The Company shall pay such interest in arrears quarterly on the last day of each March, June, September and December, on any day any portion of the principal balance is repaid or prepaid. No amount has been drawn under the Promissory Note by the Company during the years ended December 31, 2018 or 2017, and as such, no interest expense has been incurred by the Company during the years ended December 31, 2018 or 2017.

B. FHLB Agreements

(1) The Company is a member of the FHLB of Des Moines. Through its membership, the Company is eligible to borrow under variable rate short-term federal fund arrangements to provide additional liquidity. During 2018, the Company borrowed \$183.0 million from the FHLB through their variable rate short-term federal funds program, which was accounted for as borrowed money under SSAP No. 15, *Debt and Holding Company Obligations*. The borrowing matured on August 24, 2018 and carried an interest rate of 2.16%, with interest due at maturity. The Company incurred interest expense on the short-term borrowing of \$1.3 million for the year ended December 31, 2018. There were no borrowings outstanding under the short-term federal funds borrowing arrangement as of December 31, 2018.

The Company has issued funding agreements to the FHLB of Des Moines in exchange for cash resulting in a liability of \$913.0 million as of December 31, 2018. The Company uses these funds in an investment spread strategy, consistent with its other investment spread operations. As such, the Company applies SSAP No. 52, *Deposit-Type Contracts*, accounting treatment to these funds, consistent with its other deposit-type contracts. It is not part of the Company's strategy to utilize these funds for operations, and any funds obtained from the FHLB of Des Moines for use in general operations would be accounted for consistent with SSAP No. 15 as borrowed money.

^{**} I - Immaterial or M - Material

(2) FHLB Capital Stock

The Company must provide appropriate collateral to borrow under the arrangements described above. The borrowing capacity available to the Company under these agreements is largely a factor of the Company's ability to post eligible collateral, as well as internal limits such as single-holder exposure limits (10% of the entity's balance sheet liabilities) and NAIC capital requirements.

The tables below indicate the amount of FHLB of Des Moines stock purchased, collateral pledged, assets and liabilities related to the agreements with FHLB of Des Moines.

Current Year		Tot	al 2+3	General Account	Separate Account	ts
1. Odifork Todi		•		-		
(a) Membership Stock - Class	s A					
(b) Membership Stock - Class	s B		10,000,000	10,000,000		
1				37,048,000		
· · · · · ·						
` '	1)					
			47,040,000	47,048,000		••••
	wing Capacity as Determined by		500,000,000	xxx	XXX	
2. Prior Year-end						
	s A					
` ,	B			10,000,000		
` ,						
• •				21,904,000		
` '						
	i)		31,904,000	31,904,000		••••
	wing Capacity as Determined by		500,000,000	XXX	XXX	
11B(2)a2(f) should be equal	al to or greater than 11B(4)a1(o al to or greater than 11B(4)a2(o	d)				
o. Membership Stock (Class A and	B) Eligible and Not Eligible for I	Redemption 2		Eligible for	Redemption	
	Current Year		3	4	5	_
	Total (2+3+4+5+6)	Not Eligible for Redemption	Less Than 6 Months	6 Months to Less Than 1 Year	1 to Less Than 3 Years	3 to :
Membership Stock		•				
1. Class A						
2. Class B						
11B(2)b1 Current Year Total (Colu 11B(2)b2 Current Year Total (Colu						
Collateral Pledged to FHLB . Amount Pledged as of Reporting	Date					
/ incum r loaged do or reporting	Bato	1		2	3	
					Aggregate Total	
		Fair \	/alue	Carrying Value	Borrowing	_
1. Current Year Total General a	and Separate Accounts Total	4.0	-0.00.000	4 000 540 400	000 000 00	^
Collateral Pledged (Lines 2+3	3)			1,220,540,486	926,200,00	
Collateral Pledged (Lines 2+3 2. Current Year General Account	3)int Total Collateral Pledged	1,2	56,829,839	1,220,540,486	926,200,00	
Collateral Pledged (Lines 2+3	3)int Total Collateral Pledged	1,2	56,829,839	1,220,540,486		
Collateral Pledged (Lines 2+3 2. Current Year General Accounts 3. Current Year Separate Accounts 4. Prior Year-end Total General	3)int Total Collateral Pledged nt Total Collateral Pledged	1,25	56,829,839	1,220,540,486		0
Collateral Pledged (Lines 2+3 2. Current Year General Accounts 3. Current Year Separate Accounts 4. Prior Year-end Total General	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than should be equal to or less than should be equal to or less than		56,829,839 45,248,016 ans 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res	1,220,540,486 	926,200,00	0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than		56,829,839 45,248,016 ans 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res	1,220,540,486 	926,200,00	 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than		56,829,839 45,248,016 ans 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res	1,220,540,486 	926,200,00	0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than	94 n 11B(3)b1 (Colum n 11B(3)b2 (Colum n 11B(3)b3 (Colum n 11B(3)b4 (Colum	56,829,839 45,248,016 ans 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res			 0 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than	n 11B(3)b1 (Colum n 11B(3)b2 (Colum n 11B(3)b3 (Colum n 11B(3)b4 (Colum n 11B(3)b4 (Colum	56,829,839 45,248,016 ans 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res ans 1, 2 and 3 res	1,220,540,486 		 0 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than		56,829,839 45,248,016 ans 1, 2 and 3 res ins 1, 2 and 3 res ins 1, 2 and 3 res ans 1, 2 and 3 res			0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Reporting Period		56,829,839 45,248,016 ans 1, 2 and 3 res ans 1, 2 and 3 res ans 1, 2 and 3 res ans 1, 2 and 3 res	1,220,540,486		 0 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Separate Accounts Maximu 3)		56,829,839 45,248,016 45,248,016 ans 1, 2 and 3 res ans 1, 2 and 3 res ans 1, 2 and 3 res 2 and 3 res	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Separate Accounts Maximu and Separate Accounts Maximu nt Maximum Collateral Pledged	1,25 1,118(3)b1 (Column 1118(3)b2 (Column 1118(3)b3 (Column 1118(3)b4 (Column 1118(3	56,829,839 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	 0 0 t t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Reporting Period and Separate Accounts Maximu 3)		56,829,839 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016 45,248,016	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	 0 0 t t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal		756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Reporting Period and Separate Accounts Maximu 3)		756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal		756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	00 00 tt
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal		756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	00 00 tt
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal		56,829,839 45,248,016 45,248,016 45,248,016 45,248,016 41,2 and 3 resums 1, 2 and 3 resums	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	 0 0 t 0 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	nt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Separate Accounts Maximum and Separate Accounts Maximum Maximum Collateral Pledged unts Maximum Collateral Pledged I and Separate Accounts Maximum I an	1,25 1,118(3)b1 (Column 118(3)b2 (Column 118(3)b3 (Column 118(3)b4 (Column	756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t t 0 0 0 0 0 0 0 0 0 0 0 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal	1,2! 11B(3)b1 (Column 11B(3)b2 (Column 11B(3)b4 (Column	756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t t 0 0 0 0 0 0 0 0 0 0 0 0
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	mt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Separate Accounts Maximum and Separate Accounts Maximum Collateral Pledged I and Separate Accounts Maximum Collateral Pledged I and Separate Accounts Maximum I Total 2+3		756,829,839	1,220,540,486	3 Amount Borrowed a Time of Maximum Collateral	0 0 0 0 0 0 s d
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	mt Total Collateral Pledged unts Total Collateral Pledged I and Separate Accounts Total should be equal to or less than and Separate Accounts Maximum and Separate Accounts Maximum Collateral Pledged I and Separate Accounts Maximum Collateral Pledged I and Separate Accounts Maximum I Total 2+3		756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal t		756,829,839	1,220,540,486	3 Amount Borrowed a Time of Maximum Collateral	0 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal t	1,25 1,25 1,118(3)b1 (Column 118(3)b2 (Column 118(3)b3 (Column 118(3)b4	756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal t	1,29 1,118(3)b1 (Colum 1,118(3)b2 (Colum 1,118(3)b3 (Colum 1,118(3)b4 (Colum 1,118(3)b4 (Colum 1,129 1	756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Total should be equal to or less than should be equal t	1,29 1,118(3)b1 (Colum 1,118(3)b2 (Colum 1,118(3)b3 (Colum 1,118(3)b4 (Colum 1,118(3)b4 (Colum 1,129 1	756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Maximum Collate	1118(3)b1 (Column 1118(3)b2 (Column 1118(3)b3 (Column 1118(3)b4 (C	/alue /66,829,839 //alue /66,829,839 /66,829,839 /66,829,839 /66,829,839 /66,829,839 /66,829,839 /66,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 t d 4 4
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Collateral Pledged and Separate Accounts Maximum Collate	1,2! 1,2! 1,118(3)b1 (Column 118(3)b2 (Column 118(3)b3 (Column 118(3)b4	/alue /66,829,839 //alue /66,829,839 /66,829,839 /66,829,839 /66,829,839 /66,829,839 /66,829,839 /66,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 tt 0 0 0 s dd 4 4
Collateral Pledged (Lines 2+3 2. Current Year General Accour 3. Current Year Separate Accour 4. Prior Year-end Total General Collateral Pledged	and Separate Accounts Maximum Separate Accounts Maximum Collateral Pledged and Separat	1,2! 1,2! 1,118(3)b1 (Column 118(3)b2 (Column 118(3)b3 (Column 118(3)b4	756,829,839	1,220,540,486	3 Amount Borrowed at Time of Maximum Collateral	0 0 0 tt 0 0 0 s dd 4 4 0

b. Maximum Amount During Reporting Period (Current Year)

	1	2	3
	Total 2+3	General Account	Separate Accounts
1. Debt	183,000,000	183,000,000	
2. Funding Agreements	926,200,000		926,200,000
3. Other			
4. Aggregate Total (Lines 1+2+3)	1,109,200,000 1B(4)a1(d) (Columns 1, 2	183,000,000 2 and 3 respectively)	926,200,000

c. FHLB - Prepayment Obligations

Note 12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

- A. Defined Benefit Plans: NONE
- B, C, D. Not applicable.
 - E. Defined Contribution Plans

The Company is allocated a portion of the costs related to a qualified contribution savings and retirement plan sponsored by AUSA. The plan is a qualified 401(k) plan covering officers and employees. The plan provides only non-discretionary company matching contributions. Expenses allocated to the Company from the plans for AUSA's contributions amounted to \$4.6 million and \$3.9 million for 2018 and 2017, respectively.

- F. Multiemployer Plans: NONE
- G. Consolidated/Holding Company Plans: NONE
- H. Postemployment Benefits and Compensated Absences

The Company participates in a post-retirement medical benefit plan sponsored by AUSA. The plan is unfunded and the benefits are generally based on a combination of age and years of service at retirement. The allocated expense amounted to \$0.1 million and \$0.2 million for 2018 and 2017, respectively.

The Company has deferred compensation plans for agents, officers and directors, which are not funded by the Company. The liabilities for these plans are included on Page 3, Line 21. These plans were frozen as of December 31, 2016.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17): NONE

Note 13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

- (1) At December 31, 2018 the Company has authorized and issued 10.0 million shares of \$1 par common stock which are outstanding and owned by AADE.
- (2) Preferred stock: NONE
- (3) The payment of dividends by the Company to its parent is regulated under Iowa law. Under Iowa law, the Company may pay dividends only from the earned surplus arising from its business and must receive the prior approval (or non-disapproval) of the Iowa Insurance Commissioner to pay any dividend that would exceed certain statutory limitations.

In connection with the acquisition of Aviva USA during 2013, AHL entered into a Net Worth Maintenance Agreement to provide capital support to the Company such that AHL is obligated to maintain the Company's capital and surplus in an amount sufficient to maintain the Company's total adjusted capital to be at least 200% of company action level risk based capital. The agreement also provides that the Company will not pay any dividends if such dividends would cause the company action level risk based capital ratio to fall below 200%.

- (4) No dividends were paid by the Company during 2018 or 2017.
- (5) Within the limitations presented in item (3), above, the Company may pay dividends in 2019 of \$152.7 million.
- (6) The unassigned surplus is held for the benefit of the Company's shareholder.
- (7) Unpaid advances to surplus: NONE
- (8) No shares of stock are held by the Company, including stock of affiliated companies, for special purposes.
- (9) Changes in balances of special surplus: NONE
- (10) The portion of unassigned funds (surplus) represented or reduced by unrealized gains and (losses), net of capital gains tax is \$75.0 million at December 31, 2018.
- (11) Surplus Notes: NONE
- (12) (13) Quasi-reorganization: As discussed in Note 1, during the quarter ended March 31, 2017 the Company recorded a surplus reset under SSAP No. 72 in the amount of \$1,502.3 million, resulting in a reclassification between unassigned surplus and gross paid-in and contributed surplus.

Note 14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

(1) As of December 31, 2018, the Company has unfunded commitments to invest in certain bonds and partnership interests. The total unfunded commitments are \$1,310.2 million.

The Company has guaranteed the tenant obligations of a former affiliate, Aviva Investors Americas LLC, under a lease of premises located on the 21st floor of 375 Park Avenue, New York City. The Company has been indemnified for any liability relating to this guarantee under the terms of the stock purchase agreement between Aviva plc and AHL.

(2)

(1)	(2)	(3)	(4)	(5)
('')	(2)	(0)	Maximum	(0)
			potential	
			amount of	
	Liability		future	
	recognition of		payments	
	quarantee.		(undiscounted)	
	(Include		the guarantor	
	amount		could be	
	recognized at		required to	
	inception.		make under	
	If no initial		the guarantee.	
	recognition,		If unable to	Current status of payment or
Nature and circumstances of guarantee	document	Ultimate financial statement		performance risk of quarantee.
and key attributes, including date and	exception	impact if action under the	estimate, this	Also provide additional discussion
duration of agreement	allowed under	quarantee is required	should be	as warranted
duration of agreement	SSAP No. 5R.)		specifically	as warranteu
	33AF NO. 3K.)		noted.	
Cuarantae the tenent obligations of		Rent payable under the	noted.	The Company has been
Guarantee the tenant obligations of former affiliate Aviva Investors Americas		lease is \$1,979,647 per		indemnified for any liability relating
LLC under lease of premises located on		annum.		to this guarantee under the terms
the 21st floor of 375 Park Avenue, New		aililuiii		of the stock purchase agreement
York City. In addition to guaranteeing				between Aviva plc and AHL. No
the payment of rent under the lease, the				liability has been recorded for the
Company has guaranteed the payment				Company's obligation under this
of all additional rent due under the lease				guarantee. Given the lack of
and agreed to indemnify the landlord				performance risk by Aviva
from any out-of-pocket loss, costs or				Investors Americas LLC and the
damages arising out of any failure by				existence of the indemnification,
Aviva Investors Americas LLC to pay or				*
perform any of its obligations under the				the fair value of the guarantee has been determined to be \$0.
lease including, without limitations,				been determined to be 40.
reasonable attorneys' fees and costs of				
collection. This guarantee arose due to				
the landlord's requirement that an entity				
with publicly available financial				
information serve as guarantor. The				
lease term runs through April 30, 2020.				
9		2007		2007
Total		XXX		XXX

(3) Only one guarantee has been made by the Company. Aggregate compilation is not necessary given the indemnification noted above.

B. Assessments

(1) Based on the 2018 National Organization of Life and Health Insurance Guaranty Associations (NOLHGA) Report, the Company has identified insolvencies. The Company fulfilled premium-based guaranty funds assessments of \$0.2 million during the current period. It is expected that the identified insolvencies will result in retrospective premium-based guaranty fund assessments against the Company. During 2018, future estimated costs to be assessed against the Company, from identified insolvencies from the NOLHGA Report were reduced by less than \$0.1 million, which has been credited to operations in the current period and the liability reduced.

- (3) The Company does not have guaranty fund liabilities or assets related to assessments from insolvencies of entities that wrote long-term care contracts.
- C. Gain Contingencies: NONE
- D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits: NONE
- E. Joint and Several Liabilities: NONE

F. All Other Contingencies

On July 27, 2015, John Griffiths, on behalf of himself and others similarly situated, filed a putative class action complaint in the United States District Court for the District of Massachusetts. An amended complaint was filed on December 18, 2015. The complaint asserts claims against AHL, the Company and Athene London Assignment Corporation (Athene London), in addition to an Aviva defendant. AHL is a named defendant due to its purchase of Aviva USA Corporation, and the Company and Athene London are named as successors to Aviva Life Insurance Company and Aviva London Assignment Corporation, respectively. The complaint alleges a putative class of all persons who are the beneficial owners of assets which were used to purchase structured settlement annuities that Aviva Life Insurance Company, Aviva London Assignment Corporation, and Aviva International Insurance Limited (collectively, the Aviva Entities) or their predecessors, as applicable, delivered to purchasers on or after April 1, 2003 that were backed by a capital maintenance agreement issued by Aviva International Insurance Limited or its predecessor (the CMA). The complaint alleges that the Aviva Entities sold structured settlement annuities to the public on the basis that such products were backed by the CMA, which was alleged to be a source of great financial strength. The complaint further alleges that the Aviva Entities used the CMA to enhance the sales volume and raise the price of the annuities. The complaint claims that, as a result of Aviva USA Corporation's sale to AHL, the CMA terminated. According to the complaint, no notice of this termination was provided to the owners of the structured settlement annuities. The complaint alleges that the termination of the CMA gave rise to claims for breach of contract, breach of fiduciary duty, promissory estoppel, and unjust enrichment. On October 23, 2018, the Court granted final approval of the settlement. On November 8, 2018, the Court dismissed the action pursuant to the settlement approval which requi

The Company and certain of its insurance subsidiaries have experienced increased service and administration complaints related to the conversion and administration of the block of life insurance business acquired in connection with Athene Holding Ltd.'s acquisition of Aviva USA Corporation and reinsured to affiliates of Global Atlantic Financial Group Ltd. The life insurance policies included in this block have been and are currently being administered by AllianceOne, a subsidiary of DXC Technology Company, which was retained by such Global Atlantic affiliates to provide services on such policies. AllianceOne also administers certain annuity policies that were on Aviva USA Corporation's legacy policy administration systems that were also converted in connection with the acquisition of Aviva USA Corporation and have experienced similar service and administration issues.

As a result of the difficulties experienced with respect to the administration of such policies, Athene received notifications from several state regulators, including but not limited to the New York Department of Financial Services (NYDFS), the California Department of Insurance and the Texas Department of Insurance, indicating, in each case, that the respective regulator planned to undertake a market conduct examination or enforcement proceeding of the Company or one of its subsidiaries, as applicable, relating to the treatment of policyholders subject to Athene reinsurance agreements with affiliates of Global Atlantic and the conversion of such annuity policies, including the administration of such blocks by AllianceOne. On June 28, 2018, Athene Life Insurance Company of New York (ALICNY) entered into a consent order with the NYDFS resolving that matter in a manner that ultimately did not have a material impact on its financial condition, when considering AHL's indemnification from affiliates of Global Atlantic, which was passed to ALICNY in the form of a capital contribution in the third quarter of 2018.

In addition to the foregoing, the Company has received inquiries, and expects to continue to receive inquiries, from other regulatory authorities regarding the conversion matter. In addition to the examinations and proceedings initiated to date, it is possible that other regulators may pursue similar formal examinations, inquiries or enforcement proceedings and that any examinations, inquiries and/or enforcement proceedings may result in fines, administrative penalties and payments to policyholders. The Company is not currently able to estimate the amount of any such fines, penalties or payments arising from these matters with reasonable certainty, but it is possible that such amounts may be material.

Pursuant to the terms of the reinsurance agreements between Athene and the relevant affiliates of Global Atlantic, the applicable affiliates of Global Atlantic have financial responsibility for the ceded life block and are subject to significant administrative service requirements, including compliance with applicable law. The agreements also provide for indemnification to Athene, including for administration issues.

On January 23, 2019, the Company received a letter from the NYDFS, with respect to a recent Pension Risk Transfer (PRT) transaction, which expressed concerns with the Company's interpretation and reliance upon certain exemptions from licensing in New York in connection with certain activities performed by employees in the PRT channel, including specific activities performed within New York. The Company is currently in discussions with the NYDFS to identify approaches to resolve its concerns. Reasonably possible losses, if any, cannot be estimated at this time.

In 2000 and 2001, two insurance companies which were subsequently merged into the Company purchased from American General Life Insurance Company (American General) broad based variable corporate-owned life insurance (COLI) policies that, as of December 31, 2018, had an asset value of \$361.7 million. In January 2012, the COLI policy administrator delivered to the Company a supplement to the existing COLI policies and advised that American General and ZC Resource Investment Trust (ZC Trust) had unilaterally implemented changes set forth in the supplement that if effective, would: (1) potentially negatively impact the crediting rate for the policies and (2) change the exit and surrender protocols set forth in the policies. In March 2013, the Company filed suit against American General, ZC Trust, and ZC Resource LLC in Chancery Court in Delaware, seeking, among other relief, a declaration that the changes set forth in the supplement were ineffectual and in breach of the parties' agreement. The parties filed cross motions for judgment as a matter of law, and the court granted defendants' motion and dismissed without prejudice on ripeness grounds. The issue that negatively impacts the crediting rate for one of the COLI policies has subsequently been triggered and on April 3, 2018, the Company filed its suit against the same defendants in Chancery Court in Delaware seeking substantially similar relief, which defendants have moved to dismiss and the Company has opposed. The Court heard oral arguments on February 13, 2019 and has taken the matter under advisement. If the supplement is ultimately deemed to be effective, the purported changes to the policies could impair the Company's ability to access the value of guarantees associated with the policies. The value of the guarantees included within the asset value reflected above is \$187.2 million as of December 31, 2018.

On April 6, 2016, the U.S. Department of Labor (DOL) issued the fiduciary rule which imposes upon third parties who sell annuities within Employee Retirement Income Security Act of 1974 (as amended, ERISA) plans or to individual retirement account (IRA) holders a fiduciary duty to retirement investors. On June 21, 2018, the Fifth Circuit Court of Appeals issued a mandate officially vacating as a whole the DOL's 2016 Fiduciary Rule.

The U.S. Securities and Exchange Commission (SEC) has indicated that it will work with the DOL to propose rules creating a uniform standard of conduct applicable to broker-dealers and investment advisers in 2019, which, if adopted, may affect the distribution of the Company's products. The NAIC is working to propose changes to the Suitability in Annuity Transactions Model Regulation and some states separately are updating their suitability regulations to include the best interest concept. Should the SEC, NAIC, or state specific rules, once adopted, not align, the distribution of the Company's products could be further complicated.

In addition to the cases previously discussed, the Company is routinely involved in litigation and other proceedings, reinsurance claims and regulatory proceedings arising in the ordinary course of its business. At present, no contingencies related to pending litigation and regulatory matters are considered material in relation to the financial position of the Company.

Note 15. Leases: NONE

Note 16. Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk

(1) The table below summarizes the face amount of the Company's financial instruments with off-balance sheet risk.

	ASS	SETS	LIABII	LITIES	
	2018	2017	2018		
a. Swaps	1,386,980,247	272,611,042	615,827,040		
b. Futures	2,025	2,142	1,176	1,180	
c. Options	32,992,889,916	28,726,383,325	317,059,918	950,984,057	
d. Total	34.379.872.188	28.998.996.509	932.888.134	2.245.899.897	

- (2) The Company's futures, swaps, and options have off-balance sheet risk. See Note 8 for information regarding the Company's derivative instruments.
- The Company is exposed to credit-related losses in the event of nonperformance by counterparties on derivative instruments. The Company does not anticipate non-performance by any of these counterparties. Purchasing instruments from financial institutions with high credit ratings minimizes the credit risk associated with such instruments. The amount of exposure is represented by the fair value (market value) at the reporting date less any posted collateral. Collateral support documents are negotiated to further reduce this exposure where deemed necessary. Exchange-traded derivatives are affected through a regulated exchange and positions are marked to market daily.
- (4) The counterparty may be required to post collateral for any derivative contracts that are entered. The amount of collateral that is required is determined by the market value and credit threshold of the counterparty.

The current credit exposure of the Company's derivative contracts is limited to the fair value at the reporting date less collateral held. Credit risk is managed by entering into transactions with creditworthy counterparties and obtaining collateral where appropriate and customary. The Company also attempts to minimize its exposure to credit risk through the use of various credit monitoring techniques. 100% of the net credit exposure for the Company from derivative contracts is with investment-grade counterparties.

Note 17. Sale, Transfer and Servicing of Financial Assets and Extinguishment of Liabilities

- A. Transfers of Receivables Reported as Sales: NONE
- B. Transfer and Servicing of Financial Assets: NONE
- C. Wash Sales
 - (1) In the course of the Company's asset management, securities have been sold and reacquired within 30 days of the sale date to enhance the Company's yield on its investment portfolio.
 - (2) The details by NAIC designation 3 or below, or unrated securities sold during the year ended December 31, 2018 and reacquired within 30 days of the sale date are:

	NAIC	Number of	of	Securities	
Description	Designation	Transactions	Securities Sold	Repurchased	Gain/(Loss)
Bonds	3	1	1,477,500	1,477,851	(351)

Rook Value

Cost of

Note 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans: NONE

Note 19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators: NONE

Note 20. Fair Value Measurements

- A. Fair Value Measurements
 - (1) Fair value measurements at reporting date

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
a. Assets at fair value	,	,	, ,	,	
Bonds: Corporates		179.204			179.204
Bonds: CMBS					
Bonds: RMBS		523,251			523,251
Common stocks unaffiliated	38,455,956	47,049,822	2,489,736		87,995,514
Derivative assets: Bond hedges					
Derivative assets: Currency swaps		2,762,349			2,762,349
Derivative assets: Interest rate swaps					
Derivative assets: Futures					
Derivative assets: Forwards					
Separate account assets: Variable products		28,603,153			28,603,153
Total assets at fair value/NAV	44,287,893	79,717,954	2,489,736		126,495,583

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
b. Liabilities at fair value					
Derivative liabilities: Bond hedges		730,500			730,500
Derivative liabilities: Total return swaps		2,723,927			2,723,927
Derivative liabilities: Variance swaps		783,336			783,336
Derivative liabilities: Futures	1,459,963				1,459,963
Derivative liabilities: Forwards		2,009,361			2,009,361
Separate account liabilities: Variable products		28,603,019			28,603,019
Total liabilities at fair value	1,459,963	34,850,143			36,310,106

There were no transfers between Level 1 and Level 2 of the fair value hierarchy during 2018.

(2) Fair value measurements in (Level 3) of the fair value hierarchy

Description	Beginning Balance at 01/01/2018	Transfers into Level 3	Transfers out of Level 3	and (losses)	Total gains and (losses) included in Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance at 12/31/2018
a. Assets										
Common stocks unaffiliated	376,723		(2,508)		2,115,480	41				2,489,736
Total Assets	376,723		(2,508)		2,115,480	41				2,489,736

Assets transferred out of Level 3 primarily included assets the Company previously priced by using an internal model but is now able to obtain pricing from a recognized external pricing source.

- (3) Transfers between fair value hierarchy levels are recognized at the end of the period in which the transfer occurs.
- (4) The following discussion describes the valuation methodologies and inputs used for assets and liabilities measured and disclosed at fair value. The techniques utilized in estimating the fair values of financial instruments are reliant on the assumptions used.

Fair value estimates are based on quoted market prices when available. When quoted market prices are not available, the Company utilizes commercially available pricing vendors that utilize observable market inputs, like recent trading activity, to derive fair value. When vendor prices are not available, fair value is generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality (matrix pricing). In instances where there is little or no market activity for the same or similar instruments, the Company estimates the fair value using methods, models and assumptions that management believes market participants would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment which becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect risk inherent in a particular methodology, model or input employed.

The Company's financial assets and liabilities carried at estimated fair value have been classified, for disclosure purposes, based on a hierarchy defined by current accounting guidance. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The levels of the fair value hierarchy are as follows:

Level 1 - Unadjusted quoted prices for identical assets or liabilities in an active market.

Level 2 - Quoted prices for inactive markets or valuation techniques that require observable direct or indirect inputs for substantially the full term of the asset or liability.

Level 2 inputs include the following:

- 1. Quoted prices for similar assets or liabilities in active markets,
- 2. Observable inputs other than quoted market prices, and
- 3. Observable inputs derived principally from market data through correlation or other means.

Level 3 - Prices or valuation techniques with unobservable inputs significant to the overall fair value estimate. These valuations use critical assumptions not readily available to market participants. Level 3 valuations are based on market standard valuation methodologies, including discounted cash flows, matrix pricing, or other similar techniques.

Assets and liabilities are valued as discussed below in part C.

- B. Other Fair Value Disclosures: NONE
- C. Aggregate fair value for all financial instruments and the level within the fair value hierarchy in which the fair value measurements in their entirety fall.

							Not Practicable
	Aggregate	Admitted				Net Asset	(Carrying
Town of Cinemaial Instrument			(1 1 4)	(11 0)	(11 2)		
Type of Financial Instrument	Fair Value	Assets	(Level 1)	(Level 2)		Value (NAV)	Value)
Assets - Bonds							
Assets - Preferred stocks	118,416,506	121,789,115		118,416,506			
Assets - Common stocks unaffiliated	87,995,515	87,995,515	38,455,956	47,049,823	2,489,736		
Assets - Mortgage loans - first liens	6,136,598,355	6,070,077,813			6,136,598,355		
Assets - Mortgage loans - other than first liens	1,641,130,080	1,639,441,726			1,641,130,080		
Assets - Policy loans	189,508,910	189,508,910		189,508,910			
Assets - Cash and short-term investments	1,444,252,818	1,444,252,897	1,443,752,961	499,857			
Assets - Derivative assets							
Assets - Derivative collateral assets	42,236,577	42,236,577	42,236,577				
Assets - Other invested assets							
Assets - Separate account: variable products	28,603,153	28,603,153		28,603,153			
Assets - Separate account: group annuity	4,704,855,127	4,859,199,705	555,001,631	3,498,234,610	629,917,978	21,700,908	
Liabilities - Deposit-type contracts	448,010,726	435,597,932			448,010,726		
Liabilities - Derivative liabilities	76,359,967	39,463,437	18,639,320	53,731,976	3,988,671		
Liabilities - Derivative collateral liability							
Liabilities - Separate account: funding agreements	936,161,170	912,994,994		936,161,170			
Liabilities - Separate account: group annuity deposit-							
type contracts	705,438	719,053			705,438		

Bonds and short-term investments – The Company obtains the fair value for most marketable, public bonds without an active market from several commercial pricing services. These are classified as Level 2 assets. The pricing services incorporate a variety of market observable information in their valuation techniques, including benchmark yields, broker-dealer quotes, credit quality, issuer spreads, bids, offers, and other reference data. If the Company cannot value a public bond with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3. The Company values privately placed bonds based on the credit quality and duration of comparable marketable securities, which may be securities of another issuer. In some instances, the Company uses a matrix-based pricing model. These models consider the current level of risk-free interest rates, corporate spreads, credit quality of the issuer, and cash flow characteristics of the security. Privately placed fixed maturity securities are classified as Level 2 or 3.

Preferred stocks and common stocks unaffiliated – The Company values equity securities, typically private equities or equity securities not traded on an exchange, using several commercial pricing services or an internal model. The securities priced by a commercial pricing service are classified as Level 2 and the securities priced by an internal model are classified as Level 3. In addition, unaffiliated common stocks include FHLB stock, which is carried at fair value, which is presumed to be par because it can only be redeemed by the bank and is classified as Level 2.

Mortgage loans – The Company estimates mortgage loans on a monthly basis using discounted cash flow analysis and rates being offered for similar loans to borrowers with similar credit ratings. Loans with similar characteristics are aggregated for purposes of the calculations. The discounted cash flow model uses unobservable inputs, including estimates of discount rates and loan prepayments. Mortgage loans are classified as Level 3.

Policy loans – The fair value of policy loans classified as Level 2 is equal to the carrying value of the loans, which are collateralized by the cash surrender value of the associated insurance contracts.

Derivatives – Derivative contracts can be exchange traded or over-the-counter. Over-the-counter derivatives are valued using valuation models or an income approach using third-party broker valuations. Valuation models require a variety of inputs, including contractual terms, market prices, yield curves, measures of volatility, prepayment rates, and correlation of the inputs. The Company considers and incorporates counterparty credit risk in the valuation process through counterparty credit rating requirements and monitoring of overall exposure. The Company also evaluates and includes its own nonperformance risk in valuing derivatives. The majority of the Company's derivatives trade are in liquid markets; therefore, the Company can verify model inputs and model selection does not involve significant management judgment and are classified within Level 2. If the Company cannot verify model inputs and model selection does involve significant management judgment, the derivatives are classified as Level 3.

Other invested assets – Within other invested assets, partnerships are valued based on net asset value information provided by the general partner or related asset manager. These partnership interests usually include multiple underlying investments for which either observable market prices or other valuation methods are used to determine the fair value. These investments are reported in the Net Asset Value (NAV) column. Other than partnerships, other invested assets may include surplus notes and other investments with bond or stock characteristics and the Company attempts to value these using several commercial pricing services, which would be classified as Level 2 assets. If the Company cannot value with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3 assets.

Separate account assets (variable products) – Separate account assets classified as Level 2 are valued based on the fair value of the underlying funds. Fair values and changes in the fair values of the underlying funds accrue directly to the policy owners and are not included in the Company's revenues and expenses or surplus.

Separate account assets (group annuity) – Financial instruments within this separate account classified as Level 2 and 3 or included in the NAV column are valued using the same fair value assumptions and methods utilized in the general account.

Deposit-type contracts (including separate account group annuity) – Deposit-type contracts classified as Level 3 include single premium immediate annuities (SPIA) and supplemental contracts. Fair value of SPIA and supplemental contracts are calculated by discounting best estimate cash flows based on mortality and market interest rate assumptions.

Separate account liabilities (funding agreements) – Fair value of the funding agreements within this separate account are calculated by discounting future cash flows using market rates on the valuation date, and are classified as Level 2.

D. Not Practicable to Estimate Fair Value: NONE

E. Net Asset Value

The Company invests in certain non-fixed income, alternative investments in the form of limited partnerships (investment funds) which are reported at NAV. Adjustments to the carrying amount reflect the Company's pro rata ownership percentage of the operating results as indicated by NAV in the investment fund financial statements. The NAV from the investment fund financial statements can be on a lag of up to three months when investee information is not received in a timely manner. These investments are listed in the NAV column of the fair value tables above as this is the primary method for reporting fair value for these investments.

As of December 31, 2018, the Company has \$1,092.2 million unfunded commitments to invest in these investment funds.

Note 21. Other Items

A. Unusual or Infrequent Items: NONE

B. Troubled Debt Restructuring: NONE

C. Other Disclosures

The Company is the owner and beneficiary of life insurance policies included in aggregate write-ins for other than invested assets at their cash surrender values pursuant to SSAP No. 27, Off-Balance-Sheet and Credit Risk Disclosures. At December 31, 2018, the cash surrender value in the investment vehicle was \$361.7 million and was allocated 100% to other invested assets based on the primary underlying investment characteristics.

During 2018, the Company was notified by Accordia Life and Annuity Company (Accordia) of corrections made to balances previously provided related to novated life insurance policies. As a result, 18,438 policies with statutory policy reserves of \$522.8 million were denovated during 2018. These policies were previously 100% ceded to Accordia through a coinsurance agreement entered into in 2013, and therefore the novation and subsequent denovation had no impact on the Company's balance sheet, income or capital and surplus position.

D. Business Interruption Insurance Recoveries: NONE

- State Transferable and Non-transferable Tax Credits
 - (1) Carrying value of transferable and non-transferable state tax credits gross of any related tax liabilities and total unused transferable and non-transferable state tax credits by state and in total

(1)	(2)	(3)	(4)
Description of State Transferable and Non-transferable Tax Credits	State	Carrying Value	Unused Amount
Enhanced Capital Connecticut Fund I, LLC	CT	754,768	337,844
Guaranty Fund Assessment Credits	Various	11,689	11,689
21F1999 - Total		766,457	349,533

- (2) The Company estimated the utilization of the remaining transferable and non-transferable state tax credits by projecting future premium taking into account policy growth and rate changes, projecting future tax liability based on projected premium, tax rates and tax credits, and comparing projected future tax liability to the availability of remaining transferable and non-transferable state tax credits.
- (3) Impairment loss: NONE

(4) State tax credits admitted and nonadmitted

	_	Total Admitted	Total Nonadmitted
a.	Transferable	754,768	
b.	Non-transferable	11,689	

F. Subprime-Mortgage-Related Risk Exposure

(1) The Company engages in direct lending to the subprime markets. The Company's exposure to subprime risk is primarily limited to whole mortgage loans and investments within the fixed maturity investment portfolio in the form of securities collateralized by mortgages that have characteristics of subprime lending.

The Company generally defines subprime whole mortgage loans as borrowers with impaired credit history and lower FICO scores. In 2018 and 2017, the Company invested in residential whole loans which consisted of borrowers with lower FICO scores. The price paid for the residential loans factored in the consideration of the borrower's ability to repay along with the overall credit profile of the loan. The Company will continue to monitor the performance of the subprime residential mortgage loans along with performance expectations.

The Company's portfolio also contains residential mortgage backed securities that include subprime mortgage exposure. The risk of such defaults is generally higher in the case of subprime mortgages. The acquisition value of these residential mortgage backed securities factored in the consideration of that default risk. Quarterly, we monitor and evaluate the undiscounted expected future cash flows associated with these residential mortgage backed securities based on updates to key assumptions.

(2) Direct exposure through investments in subprime mortgage loans

		(1)	(2)	(3)	(4)	(5)
					Other-Than-	
		Book/Adjusted			Temporary	
		Carrying Value			Impairment	
		(excluding		Value of Land	Losses	
		interest)	Fair Value	and Buildings	Recognized	Default Rate
a.	Mortgages in the process of					
	foreclosure	4,482,980	4,079,979	6,957,941		
b.	Mortgages in good standing	249,153,941	255,277,502	373,011,687		
C.	Mortgages with restructure terms					
d.	Total	253,636,921	259,357,481	379,969,628		

(3) Direct exposure through other investments

		(1)	(2)	(3)	(4)
					Other-Than-
			Book/Adjusted		Temporary
			Carrying Value		Impairment
			(excluding		Losses
		Actual Cost	interest)	Fair Value	Recognized
a.	Residential mortgage backed securities	715,982,524	755,061,567	801,102,658	248,149
b.	Commercial mortgage backed securities				
C.	Collateralized debt obligations				
d.	Structured securities				
e.	Equity investment in SCAs *				
f.	Other assets				
g.	Total	715,982,524	755,061,567	801,102,658	248,149

These investments % of the company's invested assets. comprise

- (4) Underwriting exposure to subprime mortgage risk through Mortgage Guaranty or Financial Guaranty Insurance coverage: NONE
- G. Retained Assets: NONE
- H. Insurance-Linked Securities (ILS) Contracts: NONE

Note 22. Events Subsequent

Subsequent events have been considered through February 27, 2019 for the statutory statement dated December 31, 2018. There have been no Type I events subsequent to the close of the books and accounts for this statement that have a material effect on the financial condition of the Company.

Type II events subsequent consisted of the following:

During February 2019, the Company terminated the compensation plans for agents, officers and directors and paid out \$42.8 million of the liability on Page 3, Line 21.

Note 23. Reinsurance

Gains on cession of inforce blocks of business are to be accounted for in accordance with Appendix A-791 of the NAIC Accounting Practices and Procedures Manual which requires that any increase in surplus (net of federal income tax) resulting from reinsurance agreements entered into or amended which involve the reinsurance of business issued prior to the effective date of the agreements shall be deferred and identified separately as a surplus item by the ceding company. Subsequent recognition of the surplus increase as income shall be reflected on a net of tax basis as earnings emerge from the business reinsured. Based on the emergence of earnings of previous reinsurance of inforce blocks of business in 2018 and 2017, \$2.1 million and \$118.2 million, respectively, was amortized into income.

Effective January 1, 2018, the Company entered into a coinsurance agreement with AADE to cede 50% of all retail annuity business issued by the Company on or after January 1, 2018. This treaty is applied prior to any further cession of this business under other treaties.

Effective January 1, 2018, the Company recaptured a modified coinsurance reinsurance agreement originally entered into with ALRe on April 1, 2017. This agreement ceded 80% of the PRT business issued on or after April 1, 2017. The Company subsequently entered into a modified coinsurance agreement with AARe effective January 1, 2018 to cede the same 80% quota share of the PRT business. The modified coinsurance reserves that were recaptured from ALRe and ceded to AARe were \$1,781.5 million as of January 1, 2018.

Effective January 1, 2018, the Company recaptured a modified coinsurance reinsurance agreement originally entered into with ALRe on October 1, 2013. The agreement ceded 80% of all fixed spread annuity and fixed spread life insurance business inforce as of October 1, 2013. The Company subsequently entered into a modified coinsurance agreement with AARe effective January 1, 2018 to cede the same 80% quota share of this business. The modified coinsurance reserves that were recaptured from ALRe and ceded to AARe were \$810.2 million as of January 1, 2018.

Effective January 1, 2018, the Company partially recaptured a modified coinsurance reinsurance agreement originally entered into with ALRe on October 1, 2013. The agreement ceded 100% of all inforce and future funding agreements in both the general and the separate accounts and 80% of all inforce (as of October 1, 2013) and future annuity business which is not covered by the fixed spread treaty. The annuity business was recaptured, and the funding agreements remain ceded to ALRe. The Company subsequently entered into a modified coinsurance agreement with AARe effective January 1, 2018 to cede the same 80% quota share of the inforce and future annuity business, after the impacts of all other reinsurance agreements are applied. The modified coinsurance reserves that were recaptured from ALRe and ceded to AARe were \$34,100.5 million as of January 1, 2018.

Effective October 1, 2018, the Company recaptured a modified coinsurance reinsurance agreement originally entered into with ALRe on October 1, 2013. The agreement ceded 100% of all inforce and future funding agreements in both the general and the separate accounts. The Company subsequently entered into a funds withheld coinsurance agreement with AARe effective October 1, 2018 to cede 100% of all inforce and future funding agreements in both the general and the separate accounts. The modified coinsurance reserves held in the separate account that were recaptured from ALRe and ceded to AARe under this funds withheld coinsurance agreement were \$691.8 as of October 1, 2018. There were no funding agreements in the general account as of October 1, 2018.

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

- (1) Are any of the reinsurers listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee or director of the Company? NO
- (2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) which is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business? NO

Section 2 - Ceded Reinsurance Report - Part A

- (1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits? NO
- (2) Does the Company have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts which, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies? NO

Section 3 - Ceded Reinsurance Report - Part B

- (1) What is the estimated amount of the aggregate reduction in surplus, for agreements not reflected in Section 2 above, of termination of all reinsurance agreements, by either party, as of the date of this statement? Where necessary the Company may consider the current or anticipated experience of the business reinsured in making this estimate. \$0
- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts which were in force or which had existing reserves established by the Company as of the effective date of the agreement? YES

If yes, what is the amount of reinsurance credits, whether an asset or a reduction of liability, taken for such new agreements or amendments?

During 2018, the Company executed reinsurance agreements including the cession of contracts in force through modified coinsurance with reserves of \$36,692.2 million and through funds withheld coinsurance with reserves of \$691.8 million. See details above.

B. Uncollectible Reinsurance: NONE

C. Commutation of Ceded Reinsurance

As discussed above, during 2018, the Company recaptured several reinsurance treaties from ALRe.

The Company has reported the following in its operations in the current year as a result of commutation of reinsurance.

- (1) Claims incurred
 (2) Claims adjustment expenses incurred

 (3) Premiums earned
 \$37,384,018,886

 (4) Other
 Amount

 (5) Company
 Amount

 Athene Life Re Ltd.
 \$37,384,018,886
- D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation: NONE
- E. Variable Annuity Reinsurance with an Affiliated Captive Reinsurer: NONE
- F. Reserve Credits Taken on Variable Annuity Reinsurance with an Affiliated Captive Reinsurer: NONE
- G. Ceding Entities That Utilize Captive Reinsurers to Assume Reserves Subject to the XXX/AXXX Captive Framework

The Company does not cede XXX/AXXX reserves to a captive affiliate with a Risk-Based Capital Shortfall or a non-zero Primary Security Shortfall.

Note 24. Retrospectively Rated Contracts & Contracts Subject to Redetermination: NONE

Note 25. Change in Incurred Losses and Loss Adjustment Expenses: NONE

Note 26. Intercompany Pooling Arrangements: NONE

Note 27. Structured Settlements: NONE

Note 28. Health Care Receivables: NONE

Note 29. Participating Policies

F.

- A. As of December 31, 2018 and 2017, 54.2% and 59.2%, respectively, of life insurance policies were participating. All participating life insurance policies are included in reinsurance agreements with Athene Re IV or Accordia.
- B. The method of accounting for policyholder dividends is based upon dividends credited annually to policyholders on their policy anniversary date plus the change from the prior period on one year's projected dividend liability on policies in force at the statement date. Source data is produced from the Company's policy administration system.
- C. The amount of dividend expense incurred was \$0 and less than \$0.1 million for the years ended December 31, 2018 and 2017, respectively.
- D. There was no additional income allocated to participating policyholders.

Note 30. Premium Deficiency Reserves: NONE

Note 31. Reserves for Life Contracts and Annuity Contracts

(1) The Company waives deduction of deferred fractional premiums upon death of insured and returns any portion of the final premium beyond the date of death. The reserve for surrender values promised in excess of the legally computed reserves is shown in Exhibit 5, Miscellaneous Reserves.

The Company offers riders on its fixed annuities which provides for future withdrawal and death benefits. In accordance with the NAIC's Accounting Practices and Procedures Manual, the rider should be reserved for under the revised Actuarial Guideline 33 (AG33). The Company requested and received approval to use an alternative methodology under the Practical Consideration section of AG 33 from the Insurance Division, Department of Commerce of the State of Iowa for policies issued prior to January 1, 2014. The reserve held at December 31, 2018 was based on Actuarial Guideline 43 (AG43) for policies issued prior to January 1, 2014, the approved alternative method for these contracts. For policies issued January 1, 2014 and after, the reserve was based on Actuarial Guideline 33 (AG33).

- (2) Mean reserves for substandard policies are determined by computing the regular mean reserve for the policy and holding in addition one half of the extra premium charge for the year. For payout annuities involving life contingencies, reserve for substandard policies are calculated using rated ages instead of the true issue ages of the insureds.
- (3) As of December 31, 2018, the Company had \$1,674.2 million of insurance in force for which the gross premiums were less than the net premiums according to the standard of valuation set by the State of Iowa. Reserves to cover the above shortfall in premium totaled \$36.9 million at December 31, 2018, are calculated annually, and were included in reserves on Page 3, Line 1 (Exhibit 5, Miscellaneous Reserves).
- (4) The tabular interest at December 31, 2018, (Page 7, Line 4), tabular less actual reserve released (Page 7, Line 5) and tabular cost (Page 7, Line 9) have been determined by formula as described in the NAIC instructions for Page 7.
- (5) The tabular interest on funds not involving life contingencies is calculated as the product of the mean fund balance and the average valuation interest rate.
- (6) There are no significant "Other Increases (net)" on Page 7, Line 7 or Exhibit 7, Line 4, as of December 31, 2018.

Note 32. Analysis of Annuity Actuarial Reserves and Deposit Type Liabilities by Withdrawal Characteristics

	(1)	(2)	(3)	(4)	(5)
	General	Separate Account with	Separate Account		
	Account	Guarantees	Nonguaranteed	Total	% of Total
A. Subject to discretionary withdrawal:					
(1) With market value adjustment	34,764,664,394			34,764,664,394	62.2
(2) At book value less current surrender charge of					
5% or more	3,517,441,483			. 3,517,441,483	6.3
(3) At fair value			28,603,019	28,603,019	0.1
(4) Total with market value adjustment or at fair					
value (total of 1 through 3)	38,282,105,877		28,603,019	38,310,708,896	68.6
(5) At book value without adjustment (minimal or no)				
charge or adjustment)	8,744,715,472			. 8,744,715,472	15.6
B. Not subject to discretionary withdrawal	3,228,692,331	. 5,613,024,960		. 8,841,717,291	15.8
C. Total (gross: direct + assumed)	50,255,513,680	. 5,613,024,960	28,603,019	55,897,141,659	100.0
D. Reinsurance ceded	4,959,732,403	912,994,994		. 5,872,727,397	
E. Total (net)* (C) - (D)	45,295,781,277	. 4,700,029,966	28,603,019	50,024,414,262	
* Reconciliation of total annuity actuarial reserves and d	eposit fund liabilitie	S.			

Life & Accident & Health Annual Statement:	Amount
1. Exhibit 5, Annuities Section, Total (net)	44,598,763,243
2. Exhibit 5, Supplementary Contracts with Life Contingencies Section, Total (net)	261,420,102
3. Exhibit 7, Deposit-Type Contracts, Line 14, Column 1	435,597,932
4. Subtotal	45,295,781,277
Separate Accounts Annual Statement:	
5. Exhibit 3, Line 0299999, Column 2	4,727,913,932
6. Exhibit 3, Line 0399999, Column 2	
7. Policyholder dividend and coupon accumulations	
8. Policyholder premiums	
9. Guaranteed interest contracts	
10. Other contract deposit funds	719,053
11. Subtotal	4,728,632,985
12. Combined Total	50.024.414.262

Note 33. Premium and Annuity Considerations Deferred and Uncollected

A. Deferred and uncollected life insurance premiums and annuity considerations as of the current period, were as follows:

	(1)	(2)
Туре	Gross	Net of Loading
(1) Industrial		
(2) Ordinary new business		
(3) Ordinary renewal		
(4) Credit Life		
(5) Group Life		
(6) Group Annuity		
(7) Totals	6,771,343	8,112,338

Note 34. Separate Accounts

A. Separate Account Activity

- (1) The Company maintains three separate account arrangements. The first arrangement includes one separate account containing funding agreement policies issued to the FHLB, known as Separate Account Funding Agreements. The second arrangement includes one separate account, known as ALAC Separate Account I, consisting of individual variable annuities of a non-guaranteed return nature. The third arrangement, known as Group Annuity Separate Accounts, includes three separate accounts supporting annuities payable under group fixed annuity contracts issued to various employers, or trusts established by such employers, in respect of those employers' pension plans.
- (2) In accordance with the products/transactions recorded within the separate account, some assets are considered legally insulated whereas others are not legally insulated from the general account. The legal insulation of the separate account assets prevents such assets from being generally available to satisfy claims resulting from the general account. As of December 31, 2018 and 2017, the Company's separate account statements included legally insulated assets of \$5,029.2 million and \$2,344.7 million, respectively. The assets legally insulated from the general account as of December 31, 2018, are attributed to the following products/transactions:

(1)	(1)	(2)
		Separate Account
	Legally Insulated	Assets (Not Legally
Product/Transaction	Assets	Insulated)
Separate Account - Funding Agreements		0
Separate Account I - Variable Annuities	28,603,153	
Group Annuity Separate Accounts		
Total	5,029,174,416	0

(3) The Company's variable annuity product guarantees a minimum death benefit. The Company's general account has not paid towards separate account guarantees for the past five years. The Company's variable annuity separate account has not paid risk charges for the past five years.

The Company's Group Annuity Separate Account liabilities are guaranteed by the general account. The Company's general account has not paid towards separate account guarantees during the years ended December 31, 2018 and 2017. To compensate the general account for the risk taken, the Group Annuity Separate Accounts have paid risk charges of \$8.9 million and \$1.9 million as of December 31, 2018 and 2017, respectively.

- (4) There are no securities lending transactions in the separate account.
- B. General Nature and Characteristics of Separate Accounts Business

Separate Account - Funding Agreements: The funding agreement policies are secured by the assets in the Company's general account which are not subject to claims that arise out of any other business of the Company. The funding agreement policies may not be accelerated by the holder unless there is a default under the agreement, but the Company may retire the funding agreement policies at any time. The assets and liabilities of this separate account are carried at amortized cost.

ALAC Separate Account I: Net investment experience of this separate account is credited directly to the policyholder and can be positive or negative, as determined by the performance and/or fair value of the investments held in the separate account. These variable annuities generally provide an incidental death benefit of the greater of account value or premium paid. The assets and liabilities of these accounts are carried at fair value. This business has been included in column 4 of the table below.

Group Annuity Separate Accounts: The group fixed annuity contracts obligate the Company's general account to make annuity payments if the separate account is not able to do so. The assets and liabilities of this separate account are carried at amortized cost. During 2018, the Company's general account contributed \$173.8 million of seed money to Group Annuity Separate Accounts.

Information regarding the separate accounts of the Company is as follows. All amounts are for separate accounts as of or for the year ended December 31, 2018.

	(1)	(2) Nonindexed	(3)	(4)	(5)
	Indexed	Guarantee Less than/equal to 4%	Nonindexed Guarantee More than 4%	Nonguaranteed Separate Accounts	Total
(1)	Premiums, considerations or deposits as of the end of current period	. 1,167,279,551		59,112	.1,167,338,663
	Reserves as of the end of current period				
(2)	For accounts with assets at:				
	a. Fair value			28,603,019	28,603,019
	b. Amortized cost	. 4,700,029,966			.4,700,029,966
	c. Total reserves*	. 4,700,029,966		28,603,019	.4,728,632,985
(3)	By withdrawal characteristics:				
	Subject to discretionary withdrawal:				
	With market value adjustment				
	At book value without market value adjustment and with current surrender charge of 5%				
	or more				
	3. At fair value			28,603,019	28,603,019
	4. At book value without market value adjustment and with current surrender charge less than 5%				
	5. Subtotal			28,603,019	28,603,019
	b. Not subject to discretionary withdrawal	4 700 000 066			4 700 000 066
				20 602 040	
Lino	c. Total	. 4,700,029,966		28,603,019	.4,728,632,985
LIHE	2(c) should equal Line 3(c).				
(4)	Reserves for Asset Default Risk in Lieu				
	of AVR				
Red	conciliation of Net Transfers To or (From) Separate Accou	unts			
,	ransfers as reported in the Summary of Operations of the	•			= 40 400 0 = 4
	a. Transfers to Separate Accounts (Page 4, Line 1.4)				
	b. Transfers from Separate Accounts (Page 4, Line 10)				
	c. Net transfers to or (From) Separate Accounts (a) - (b)		•••••		404,892,550
2) F	Reconciling Adjustments:				
	ransfers as Reported in the Summary of Operations of th (2) = (Page 4, Line 26)				464 802 550
	(=, (. 5g, Liiio 20)				10 1,002,000

Note 35. Loss/Claim Adjustment Expenses: NONE